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ABSTRACT
CHARACTERIZATION OF TIGHT JUNCTION FORMATION IN AN IN-VITRO MODEL OF
THE BLOOD-BRAIN BARRIER
Michael Robert Machado
Active and passive transport of substances between the microcirculation in the
brain and the central nervous system is regulated by the Blood-Brain Barrier (BBB). This barrier
allows for chronic and acute modulation of the CNS microenvironment, and protects the brain
from potentially noxious compounds carried in the circulatory system. In-vitro modeling of the
BBB has become the target of much research over the past decade, as there are many
unanswered questions regarding modulations in the permeability of this barrier. Additionally, the
development of a practical and inexpensive model of the BBB would facilitate a much more
efficient drug development process. The goal of this project is to investigate the formation of the
BBB through assessment of tight junction formation and endothelial cell monolayer
permeability. Accomplishment of this goal will include completion of the two primary aims of
this thesis, which are 1) development of an immunohistochemical staining protocol for the
labeling of tight junctional proteins, and 2) characterization of permeability across a porous
membrane co-cultured with bovine aortic endothelial cells (BAECs) and C6 glioma cells. Both
of these aims were met, as a reliable IF protocol for tight junctional staining was developed, and
permeability values across a permeable membrane seeded with BAECs and C6s were collected.
The completion of these aims has helped to accomplish the goal of investigating the formation of
tight junctions in an in-vitro model of the BBB. The IF protocol that has been developed, along
with the collected permeability data will aid the development of a more dynamic in-vitro model
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of the BBB to aid in research surrounding acute modulation of the BBB, along with facilitating a
timelier drug development process.
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v

ACKNOWLEDGEMENTS

This project would not have been possible without the help and guidance of a number of
individuals. First, I would like to thank Dr. Kristen O’Halloran Cardinal for all of her patience
and knowledgeable guidance throughout this project. You have been a phenomenal advisor, and
I have truly benefitted from working in your lab group. Your insight into each aspect of the IF
protocol development and permeability studies greatly influenced the outcome of this thesis, and
for that I thank you.
I would also like to thank the members of the Cal Poly Tissue Engineering lab, Marcus
Foley, Amin Mirzaaghaeian, Deven Patel, Mike Gibbons, Rachel Gohres, Sarah Ur, Corey
Gross, Shane Tipton, Jakob Truty, Stephan Teodosescu, and Katelyn Goodwin, for their support
throughout this project. Your knowledge and suggestions, mixed in with a little bit of Lab Pong,
spurred me through the completion of this thesis.
To Dr. Trevor Cardinal and Dr. Lily Laiho, I would like to thank you for always being
there to field my questions and to offer suggestions and solutions to the many problems I
encountered along the way. You have been tremendously influential mentors to me throughout
my years at Cal Poly, and I would not be the engineer that I am today without your guidance.
To Dr. Chad Immoos and Dr. Rafael Jimenez-Flores, I thank you for allowing me to use
equipment from the Chemistry Department and the Animal Science department during the
permeability studies of this thesis. Your eagerness to help me collect the necessary permeability
data was instrumental in the success of this project, and for that I am truly grateful.
Finally, to my loving wife Christina, I thank you for always being there to encourage me
and push me through the completion of this project. You put up with all the late nights working
in the lab, the long hours spent writing this thesis, and were even kind enough to help develop
the figures and tables contained in this document. You are always there for me, and words cannot
express my gratitude.
Again, thank you to all of my friends, family, mentors and advisors who contributed to
this thesis – none of this would have been possible without you.

vi

TABLE OF CONTENTS
List of Tables ................................................................................................................................ x
List of Figures ................................................................................................................................ xi
Chapter 1 – Introduction to the Blood-Brain Barrier .................................................................. 1
Section 1.0 General Overview ................................................................................................ 1
Section 1.1 Components of the Blood-Brain Barrier ............................................................. 1
Section 1.2 Blood-Brain Barrier-specific cell types ............................................................... 2
Section 1.2.1 Pericytes ...................................................................................................... 3
Section 1.2.2 Astrocytes ................................................................................................... 4
Section 1.2.3 Endothelial Cells ......................................................................................... 6
Section 1.3 BBB Formation In-Vivo ...................................................................................... 7
Section 1.3.1 Transport Across the BBB Endothelium .................................................. 10
Section 1.4 Pathologies Associated with Failure of the
Blood-Brain Barrier ............................................................................................ 11
Section 1.5 The Shift to In-Vitro- Models ............................................................................ 13
Section 1.5.1 Methods for Assessing BBB formation in Bench top Model ................... 14
Section 1.6 Modeling the Blood-Brain Barrier ..................................................................... 16
Section 1.6.1 Custom DIV-BBB Models ........................................................................ 19
Section 1.6.2 Current State of BBB Research in the Tissue Engineering Lab ............... 20
Section 1.7 Summary and Aims of the Thesis ...................................................................... 22

Chapter 2 – Immunofluorescence Protocol Development for Tight Junctional Proteins ......... 25
Section 2.0 Introduction ........................................................................................................ 25
Section 2.1 Methods ............................................................................................................. 26
Section 2.1.1 Study 1 - Modification to IF Protocol Version 1 ...................................... 27
Section 2.1.2 Study 2 - ZO-1 Expression as a function of Confluency .......................... 30
Section 2.1.2.1 Confluency Experiment 1 ................................................................ 31
Section 2.1.2.2 Confluency Experiment 2 ................................................................ 33

vii

Section 2.1.3 Study 3 - ZO-1 Expression as a Function of
BAEC and C6 Co-Culture ......................................................................... 35
Section 2.1.3.1 Co-Culture Study 1 - BAECs/C6s ................................................... 35
Section 2.1.3.2 Co-Culture Study 2 - C6s/BAECs ................................................... 37
Section 2.2 Study 4 - IF stain for ZO-1, Claudin-5, and PECAM-1 on
EC and C6 mono- and co-culture groups ............................................................ 41
Section 2.3 Study 5 - Blocking Buffer Experimentation ...................................................... 43
Section 2.3.1 Claudin-5 stain on C6s alone .................................................................... 43
Section 2.3.2 Final Proof of Concept IF Stain ................................................................ 45
Section 2.4 Results and Discussion ...................................................................................... 47
Chapter 3 – Assessment of the Permeability across Monolayers of Endothelial
and Glial Cells ....................................................................................................... 52
Section 3.0 Introduction ....................................................................................................... 52
Section 3.1 Methods ............................................................................................................. 53
Section 3.1.1 Study 1 - Permeability Assessment of Transwell Inserts without Cells ... 54
Section 3.1.2 Study 2 - Permeability Assessment of Transwell Inserts with Cells ........ 58
Section 3.1.2.1 Permeability of 4 kDa FITC Dextran .............................................. 59
Section 3.1.2.2 Permeability of 250 kDa FITC Dextran .......................................... 63
Section 3.1.2.3 Calculation of Permeability Coefficients for
Transwell Insert Studies ................................................................... 65
Section 3.2 Results and Discussion ...................................................................................... 66

Chapter 4 – Discussion and Conclusion ................................................................................... 69
Section 4.0 Overview ........................................................................................................... 69
Section 4.1 IF Protocol Development .................................................................................. 69
Section 4.2 Permeability Studies .......................................................................................... 74
Section 4.3 Future Work ....................................................................................................... 76
Section 4.4 Conclusion ......................................................................................................... 79

viii

References ..... .............................................................................................................................. 81
Appendix 2.0 – IF Protocol Version 1 ......................................................................................... 88
Appendix 2.1 – IF Protocol for PECAM-1 stain on hUVECs ..................................................... 89
Appendix 2.2 – IF Protocol Version 2 ......................................................................................... 90
Appendix 2.3 – Cell Culture and Passage Protocol ..................................................................... 91
Appendix 2.4 – DAKO Autostainer IF stain for ZO-1, Claudin-5, and PECAM-1
using IF Protocol Version 2 .............................................................................. 92
Appendix 2.5 – Autostainer Protocol Adapted from Senior Project by Nicholas Hanne ............ 97
Appendix 2.6 – Protocol for IF Stain for ZO-1, Claudin-5, and PECAM-1 on C6 only,
BAEC only, C6/BAEC, BAEC/C6, and Mix Experimental Groups .............. 105
Appendix 2.7 – Results from IF Stain for ZO-1, Claudin-5, and PECAM-1 on C6 only,
BAEC only, C6/BAEC, BAEC/C6, and Mix Experimental Groups ............... 106
Appendix 2.8 – IF Protocol Version 3 ....................................................................................... 124
Appendix 2.9 – Permeability Testing Protocol .......................................................................... 125

ix

LIST OF TABLES
Table 1 – Filter Wheel Settings ...........................................................................................Page 28
Table 2 – Cell Counts ...........................................................................................................Page 94
Table 3 – Permeability Coefficients .....................................................................................Page 66

x

LIST OF FIGURES

Figure 1 – Proteins involved in Tight Junction Formation .....................................................Page 2
Figure 2 – Orientation of Cells involved in BBB ...................................................................Page 3
Figure 3 – Rosette-like Structures formed by Astrocytes.......................................................Page 5
Figure 4 – Occlusion of Intercellular Clefts by Tight Junctions.............................................Page 9
Figure 5 – Methods of Transport ..........................................................................................Page 10
Figure 6 – CellMax Duo Hollow Fiber Bioreactor...............................................................Page 21
Figure 7 – Orientation of Experimental groups for IF Stain.................................................Page 28
Figure 8 – Widefield Fluorescence Microscope ...................................................................Page 28
Figure 9 – BAEC and HUVEC IF Stain ...............................................................................Page 30
Figure 10 – Distribution of BAECs in 6-well Plates ............................................................Page 31
Figure 11 – ZO-1 Expression as a Function of Confluency Part 1.......................................Page 32
Figure 12 – ZO-1 Expression as a Function of Confluency Part 2.......................................Page 34
Figure 13 – Orientation of Cells in Co-culture, BAECs over C6 .........................................Page 36
Figure 14 – Location of Cells for IF Stain............................................................................Page 36
Figure 15 – White Light Images ...........................................................................................Page 37
Figure 16 – Orientation of Cells in Co-culture, C6 over BAECs .........................................Page 38
Figure 17 – Location of Cells for IF Stain............................................................................Page 38
Figure 18 – Results of IF Stain .............................................................................................Page 40
Figure 19 – Location of Cells for Manual Co-Culture Stain ................................................Page 42
Figure 20 – Location of Cells for Blocking Buffer Experiment...........................................Page 44
Figure 21 – IF Results for Blocking Buffer Experiment ......................................................Page 44

xi

Figure 22 – Location of Cells for Final IF Stain...................................................................Page 45
Figure 23 – Results for Final IF Stain...................................................................................Page 46
Figure 24 – Diagram of Transwell Insert..............................................................................Page 52
Figure 25 – Location of Time Points for Initial Permeability ..............................................Page 55
Figure 26 – Transwell Insert .................................................................................................Page 55
Figure 27 – Brightness Values for Stock Solution on First Fluorometer .............................Page 56
Figure 28 – Non-normalized Fluorescence Values...............................................................Page 57
Figure 29 – Normalized Fluorescence Values ......................................................................Page 58
Figure 30 – Cross Section of Inserts Showing Cell Orientation...........................................Page 59
Figure 31 – Location of Cells for 4 kDa Study.....................................................................Page 60
Figure 32 – Seeding C6 Cells Onto Bottom of Insert...........................................................Page 60
Figure 33 – Brightness Values for Stock Solution on Second Fluorometer .........................Page 62
Figure 34 – Abluminal Concentration of 4 kDa Dextran .....................................................Page 62
Figure 35 – Location of Cells for 250 kDa Study.................................................................Page 63
Figure 36 – Abluminal Concentration of 250 kDa Dextran .................................................Page 64
Figure 37 – IF Images from Autostainer Test Run ...............................................................Page 93
Figure 38 – Orientation of Cells for Co-Culture...................................................................Page 94
Figure 39 – Location of Cells for Autostainer Run ..............................................................Page 95
Figure 40 – IF Images from Co-Culture Autostainer Run....................................................Page 96
Figure 41 – Positive Controls for BAEC Only ...................................................................Page 108
Figure 42 – Negative Controls for BAEC Only .................................................................Page 109
Figure 43 – Positive Controls for C6 Only .........................................................................Page 110
Figure 44 – Negative Controls for C6 Only .......................................................................Page 111

xii

Figure 45 – Positive Controls for BAEC Over C6 .............................................................Page 112
Figure 46 – Negative Controls for BAEC Over C6............................................................Page 113
Figure 47 – Positive Controls for C6 Over BAEC .............................................................Page 114
Figure 48 – Negative Controls for C6 Over BAEC............................................................Page 115
Figure 49 – Positive Controls for Mix ................................................................................Page 116
Figure 50 – Negative Controls for Mix ..............................................................................Page 117

xiii

Chapter 1 – Introduction to the Blood-Brain Barrier

Section 1.0

General Overview

The homeostasis and regulated molecular exchange established between the central
nervous system and the supporting microcirculation is a delicate relationship that is
maintained via the Blood-Brain Barrier (BBB)1,2. This barrier serves as both a physical and
metabolic barrier to modulations in plasma as well as circulating neurotransmitters and
toxicants capable of disrupting neural signaling3-5. The acute regulation of the
microenvironment in the brain facilitated by the BBB is critical to typical bodily function and
behavior. As such, changes in the ability of the BBB to maintain this balance can result in
pathologies including stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, and
epilepsy4,6-17. Research, therefore, has been largely focused on the development of BBB
models to aid in the understanding of these diseases. While the anatomy and the physiology of
the BBB have been well-characterized in-vivo, the development of an adequate in-vitro BBB
model is ongoing.
Section 1.1

Components of the Blood-Brain Barrier

The BBB is a discriminatory barrier formed by the enhanced interaction between
specialized endothelial cells located in the cerebral microcirculation2. The integral membrane
proteins and transport channels involved include members of the occludin and the claudin
families (See Figure 1). Specifically, these proteins are Zona Occludens 1, 2, and 3 (ZO-1-3),
Claudin 1, 3, 5, 12, junctional adhesion molecules (JAMs), endothelial selective adhesion
molecule (ESAM), glucose transporter (GLUT), vascular endothelial cadherin (VE-cadherin),
and platelet endothelial cell adhesion molecule (PECAM-1)18,19.
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Section 1.2

Blood-Brain Barrier-specific cell types

The formation and subsequent modulation of the tight junctions formed in the cerebral
microcirculation is the result of the intricate interplay between three cell types: the pericyte,
the astrocyte, and the endothelial cell (See Figure 2)2,13,20. Both up- and downregulation of
BBB permeability are influenced through paracrine interactions between the endothelium and
these other two cell types.

Figure 1| Intramembranous endothelial cell proteins associated with tight junction formation.2
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Figure 2| Three cell model of the capillaries composing the Blood Brain Barrier. This figure
shows the location and interaction between the specialized endothelial cell, the astrocyte foot
processes, and the perivascular cell.2
Section 1.2.1 Pericytes
Pericytes, which typically form around endothelial tubes, share a basement membrane
with the endothelial cells, facilitating the delivery of factors to encourage endothelial survival,
cell proliferation, migration, and differentiation20,21. These cells are involved in the regulation
of endothelial cell proliferation and differentiation in addition to synthesizing and secreting
certain vasoactive agonists. In addition to modulation in vascular tone, pericytes are
contractile in nature and contribute to changes in endothelial cell junctional leakage as a
function of contraction and relaxation21. The ratio of pericytes to endothelial cells is
considered to be highly variable, especially between tissue types (e.g. 1:1 in the retina, 1:10 in
the lungs, 1:100 in striated muscle)21. However, this data has been suggested based upon
single studies, and has yet to be verified with any statistical significance21. Overall, there is a
positive correlation between pericyte density and endothelial cell junctional tightness, along
with the level of microvascular blood pressure21. Taking this into account, the ratio in cerebral
3

capillaries has been experimentally determined to be 1 pericyte for every 3 ECs, which allows
room for enhanced interaction between the endothelium and the astrocyte foot process21.
These podocyte-like projections permeate 99% of the basement membrane in brain capillaries,
suggesting a significant interaction between astrocytes and endothelial cells20,22,22.
Section 1.2.2 Astrocytes
Astrocytes specifically target individual ECs, sending out foot processes to single
endothelial cells and forming rosette-like structures that wrap around the capillary tube (See
Figure 3). The connection between the endothelium and the astrocyte is similar to that of the
pericyte, forming its interface only 20nm away from the capillary wall (the effective thickness
of the basement membrane) through podocyte-like projections referred to as astrocytic
endfeet. These endfeet that attach to the circumference of cerebral capillaries are known to aid
in regulation of brain ion volume and concentration, and are necessary for the formation of the
tube-like capillary structures in vitro2. This close relationship between the endfeet of the
astrocytic glia and the endothelial cells strongly suggest maintenance and even induction of
BBB-specific characteristics in the cerebral microvasculature due to the interaction between
these two cell types. Indeed, in vitro BBB setups involving research surrounding co-culture of
astrocytes and brain capillary endothelial cells has shown the necessity for the presence and
interaction between these two cell types for the proper formation of tight junctions1,23-26.
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Figure 3| Schematic depicting the rosette-like structures formed around the endothelial cells
by the astrocytic end feet.1
Studies surrounding endothelial cell and astrocyte interaction have supported the
hypothesis that co-culture of these two cells types will increase barrier “tightness”27, showing
that the removal of astrocytes from a co-culture model results in increased permeability across
the endothelium18. However, this research has also supported that the removal of astrocytes
from a co-culture model does not reduce the expression of tight junction-specific cell surface
proteins. This suggests that while the presence of astrocytes has no bearing on the incidence
of BBB-exclusive junctional proteins, the commissioned interaction between the endothelial
cells and the astrocytes plays a vital role barrier manipulation and changes in permeability.
The origin of BBB permeability modulating agents has been shown to stem from
astrocytic cells28. These cell types have been recognized to release several humoral
compounds and modulating factors (including glutamate, aspartate, taurine, ATP, ET-1, NO,
TNFα, MIP2, IL-1β, and Bradykinin) that open the barrier, effectively increasing paracellular
transport28. These observations support the assumption that astrocytes are able to modulate
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BBB permeability through ligand-receptor communication over short time scales28.
Additionally, the relationship between the glia and the ECs has been shown to influence gene
expression through the upregulation of specific transport pathways, including GLUT-1, and Lsystem and A-system amino acid carriers29. Supplementing the modifications in extracellular
transport, astrocytes express their own membrane bound proteins (e.g. p-glycoprotein) that aid
in transcellular transport of drugs. These efflux channels such as Pgp allow for changes in
drug concentration within the brain microenvironment without modifications to endothelial
cell permeability20.
Section 1.2.3 Endothelial Cells
While signals from the pericytes and the astrocytes play a role in influencing the
function of the barrier, the key cell type involved in tight junction formation is the brain
microvessel endothelial cell. Despite the vital function in cerebral microenvironment
homeostasis, there is only a small fraction of these cell types present in the brain, with a total
EC volume per gram of brain tissue of 1µL (2% of the total brain volume)20 compared to the
almost 50% of the brain volume taken up by astrocytes30. However, it is not the amount of
cells present in the brain capillaries, but the membrane-bound proteins expressed that set apart
these specialized endothelial cells. As previously mentioned, the combination of the
expression of unique receptors, transporters, and effusive pumps provide protection for the
CNS from a wide array of potentially cytotoxic hydrophobic substances31,31,32. While retaining
the ability to target specific receptors on adjacent cells, these ECs are able to both release
cytokines and respond to them33. This suggests that despite external stimuli, the specialized
ECs in the brain are able to modulate their own permeability in response to changes in the
neural microenvironment.
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A change in the permeability of these endothelial cells is accomplished not only by the
cells themselves, but is often a result of interaction between the ECs and astrocytes. Specific
transcellular transport channels located on the astrocytic endfeet such as aquaporin-4 are
observed to be up-regulated when introduced to endothelial cells in co-culture34. In addition to
changes in protein expression, release of leukemia inhibitory factor (LIF) by the endothelium
has been shown to encourage astrocyte differentiation35.
This interaction between ECs and astrocytes has been a point of great interest during
the characterization of BBB-specific cell types. Once it became clear that the interaction of
these two cell types was favorable (and in most cases, necessary) for developing tight
junctions, endothelial cells and astrocytes have been included in most attempts to recreate the
characteristics of the BBB. Typical induction of BBB properties has been shown achieved
through physical contact between the endothelial cells and the astrocytes (astrocyte foot
processes)36. However, researchers have also demonstrated the upregulation of BBB
properties in endothelial cells introduced by using astrocyte media alone37.
Section 1.3

BBB Formation In-Vivo

To understand this complex interaction between adjacent endothelial cells (ECs), it is
important to discuss the anatomy of the three classes of capillaries (continuous, fenestrated,
and discontinuous) and their relationship to the establishment of regulated trans-endothelium
transport. In tissues such as the liver and spleen where filtration of macromolecules suspended
in the blood is necessary, capillaries exhibit sinusoids and intercellular clefts on the order of
microns, allowing the egress of compounds from the circulation38. In other tissue types where
filtration of smaller substrates and ions is conducted, fenestrated capillaries (which express
pores close to 60nm in size and tighter intercellular gaps) are responsible for regulation of
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molecular transport out of the lumen38. However, because of the narrow band of appropriate
ion and macromolecular concentrations in the CNS to support proper neuron function,
transport of any molecule across the endothelium is highly regulated by continuous
capillaries1. These capillaries exhibit extremely tight intercellular junctions, ranging from 04nm. This physical barrier severely restricts paracellular transport of large molecules39.
Additionally, these specialized endothelial cells express a unique combination of receptors
and transport channels, effectively limiting the volume and type transport of across the lumen
(e.g. endocytosis, pinocytosis, directed diffusion, and channel-mediated transport of ions and
molecules)40.
The characteristics of these capillary types responsible for this high degree of
regulated paracellular diffusion are in the form of tight junctions (TJs). These junctions can be
visualized as a complex web of intramembranous particles that effectively occlude
intercellular junctions and modulate transport across each endothelial cell (See Figure 4)1.
These tight junctions are comprised of three elements, the integral proteins and lipids, which
help to form the permeability barrier, ancillary proteins forming the intracellular element, and
the membrane-bound proteins.
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Figure 4| Structure of tight junctions between endothelial cells; junctional proteins form
webbed network between adjacent cells, effectively limiting efflux of molecules across the
lumen based upon size and charge density41.

9

Section 1.3.1 Transport Across the BBB Endothelium
The barrier established in the cerebral microvessels through the interactions of
the previously described cell types forms not only a physical barrier, limiting paracellular
exchange, but also constitutes a transcellular transport and metabolic barrier
(See Figure 5)27,42. While the physical barrier to transport is clear through the formation of
tight intracellular junctions, the transport and metabolic barriers formed by the specialized
ECs merits discussion. Compounds unable to traverse through the junctional proteins are
obliged to either interact with membrane bound receptors or molecule-specific influx/efflux
channels to stimulate transportation across the membrane. Smaller gaseous molecules such as
O2 and (sometimes) CO2 are free to diffuse through the cytoplasm along their concentration
gradients. However, other hydrophilic molecules such as glucose, amino acids, purine bases,
nucleosides, and cholines must activate transport proteins to traverse the endothelial cells31.

Figure 5| Depiction of the highly regulated transport mechanisms across blood-brain barrier.
A shows the inhibition of hydrophobic molecules through the tight junctions. Drug delivery is
typically achieved through transport mechanisms shown in B-E.2
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Likewise, specific proteins such as insulin and transferrin migrate out of the lumen
through ligand-receptor interaction, known as receptor mediated transcytosis (RMT)31. This
type of transport begins with receptor activation on the luminal side of the EC and endocytosis
of the compound. Once through the lipid bilayer, the vesicle containing the agent diffuses
through the 200 nm of cytoplasm until it is exocytosed on the abluminal side into the cerebral
interstitial space. Alternatively, certain lipophilic compounds such as caffeine and alcohol are
able to move through an EC in small vesicles via pinocytosis, or adorptive transcytosis
(Figure 5)1. While there is no determinable cutoff size for this type of transport, it is possible
to speculate on this size based upon the average size of the molecules that typically undergo
pinocytosis. Specifically, caffeine molecules, which undergo pinocytosis to cross through the
brain endothelium, can be close to 65 kDa1, comparable to other similarly lipophilic
compounds. It is has been determined that there are roughly 5 of these pinocytotic vesicles per
square micron of brain endothelium43, suggesting that this form of transport is minimally
involved in transport across the endothelium. Finally, cerebral endothelial cells can also
secrete extracellular and intracellular enzymes that interact both with luminal toxicants and
neuroactive compounds that might be transcytosed, effectively metabolizing and degrading
the agents before transport occurs44.
Section 1.4

Pathologies Associated with Failure of the Blood-Brain Barrier

Ongoing research in the area of neurological disorders has supported that a wide array
of cerebral pathologies are associated with alterations in tight junctional protein expression
and endothelial cell permeability45-47. Likewise, spontaneous changes in the structure and
function of the endothelium can result in specific neuroinflammatory diseases including
meningitis and encephalitis through interference with particular bacterial proteins48. Similarly,
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other pathological states can be attributed to breakdown of the BBB or even a deregulation of
astrocyte-endothelial coordination, including stroke, multiple sclerosis, Alzheimer’s disease,
Parkinson’s disease, and epilepsy4,6-17. In some of these cases there is a change in the typical
expression of characteristic ATP-binding cassette (ABC) transporters, such as P-glycoprotein
(Pgp), and therefore the ability of the BBB to maintain homeostatic permeability traits is
compromised16,17. Modulation of the expression of some of these ABC transporters has been
investigated as a therapeutic target49. Acute modulation of BBB permeability would allow
enhanced delivery of therapeutic agents designed to treat these disease states50. Progress in
this arena has shown significant promise in animals models, but has not resulted in
reproducible safety and efficacy in clinical trials51,52. Other therapeutic treatments for these
inflammatory conditions often include administration of glucocorticoids (GCs), which bind to
the GC receptor present on most cell types and reduce inflammation53,54. Managing
inflammation of the BBB is critical to return the permeability of the membrane back to
normal.
Chronic and acute modulations in BBB permeability have been characterized to the
greatest extent in traumatic brain injury. Research supports that an injured brain will exhibit
ruptured blood vessels in the microcirculation localized to the site of injury, and will allow the
seepage of blood contents into the brain tissue55. While this initial damage can be quite
devastating to brain microenvironment, the resulting secondary damage due to changes in
barrier permeability, which can last up to a few days following the injury, can leave lasting
effects on the CNS56. This initial damage includes loss of control over the cerebral
microenvironment and the subsequent passage of potentially toxic compounds across the
endothelial layer, further magnifying the initial damage. The timeframe during which this
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secondary damage occurs is typically within 4-6 hours, after which conventional barrier
function is restored57,58. It is important to note that while the majority of barrier function is
reestablished, effectively limiting the passage of larger (10 KDa) molecules through the
endothelium, seepage of smaller compounds can persist up to 4 days post-injury55.
Section 1.5

The Shift to In-Vitro Models

While characterization of the BBB in-vivo is vital to the expansion of our knowledge
base surrounding both typical and atypical neurological function, it is important to realize the
gradual shift in research models towards in-vitro systems tailored to mimic the natural
environment. Research and testing conducted regarding the barrier has been focused towards
the development of pharmaceuticals. While many of these studies strive to develop strategies
for clinical treatments involving BBB modulation, a large fraction of the testing is regulatory
in nature. Currently, the US Food and Drug Administration (FDA) mandates the screening of
potentially noxious compounds using animals models to determine permeability coefficients
and assess the effect of drugs-in-development on the CNS59. Typical drug validation studies in
animal models will look for sensory and/or behavioral changes in addition to histological
examinations of excised brain tissue. This type of substantiation requires large amounts of
investment dollars for the housing, care of, and subsequent testing of animals in addition to
the time demand to obtain usable data. To alleviate this pain in the drug development market
along with the development of more applicable research tools, there has been a push in the
BBB community to design novel in vitro testing procedures60. This type of model could
provide high throughput screening (HTS) of new drug compounds through a large-scale and
automated tissue engineered BBB mimic test platform.
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Standards mandating the change to in vitro test systems have already been enacted in
areas of Europe. In 2003, a gathering of the ICCVAM/ECVAM (International Coordinating
Committee on the Validation of Alternative Methods and the European Center for Validation
of Alternative Methods) developed research strategies for the ACuteTox consortium
(“Optimization and pre-validation of an in vitro test strategy for predicting human acute
toxicity”). These research strategies, which are guidelines for testing toxicity in humans,
direct researchers toward in vitro models in an effort to limit the volume of animals studies
conducted61.
While there is a desire to shift research and testing protocols from widespread animal
trials to large-scale in vitro testing programs, the complexity of modeling the natural
microenvironment to reproduce the BBB characteristics observed in vivo presents a
significant hurdle. Researchers have observed significant changes to barrier characteristics
when cultured in vitro, including down regulation in the activity of glucose and neutral amino
acid carriers, RMTs, and both luminal and intercellular antitoxic enzymes22,62. Additionally,
changes in tight junction permeability have been observed in response to extended (>60
minutes) periods of perfusion, regardless of a change in tight junctional protein expression26.
Overlooking changes in phenotype and functional characteristics, non-immortalized primary
cultures of human brain endothelial cells will rapidly dedifferentiate and begin to senesce
even in response to a moderate passaging schedule39, thus adding to the difficulties
surrounding such in-vitro modeling.
Section 1.5.1 Methods for Assessing BBB formation in Bench top Models
Due to the difficulties surrounding the development of an in-vitro BBB model, it is
essential to develop robust methods for determining tight junction formation. A
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straightforward method for determining formation of tight junctions is to measure levels of
adherence of the specialized ECs. This can be quantified by testing the electrical resistance
across a monolayer, known as transendothelial electrical resistance (TEER). An array of
TEER values for cerebral endothelial cells cultured in-vitro have been offered, ranging from
1MΩ63 to 8MΩ64. It is important to realize the difficulty in achieving in-vivo TEER values
and appropriate endothelial cell junction tightness in an in-vitro system. Is has been shown
that an in-vitro co-culture setup can take longer than 2 weeks to develop a transcellular
electrical resistance equal to ¼ that observed in vivo1. This can be enhanced through the use
of special substrata used to condition the culture flasks, such as type IV collagen and
fibronectin65. It has also been observed that fluctuations in pH and increases in buffer
concentrations (through the addition of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), or N-Tris(hydroxymethyl)methyl2-aminoethanesulfonic Acid (TES)) can have significant impacts on TEER values, potentially
through upregulation of tight junctional proteins such as claudin-566. From these results, it is
apparent that the in-vitro testing procedures currently explored by the majority of BBB
researchers are lacking fundamental intercellular communication and expression of BBBspecific membrane bound tight junctional proteins.
In order to observe the extent to which tight junctions are forming between adjacent
ECs, it is possible to tag these tight junctional proteins with a fluorescently labeled antibody.
This allows for fluorescent imaging of a monolayer of cells to reveal the presence of
intercellular proteins. Changes in endothelial cell protein expression in response to external
stimuli can therefore be quantified and optimized. An additional method for determining tight
junction formation involves the use of porous (~3µm) transwell inserts to separate the
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endothelial cells from the astrocytes while still allowing for the foot processes to reach out
and attach to the EC surface. These inserts serve as a scaffold for the cells to culture, and
establish a permeable membrane. The membrane can then be used to determine transport rate
of known compounds from one compartment to the other. As in any tissue-engineered
construct, it is also necessary to understand the cross-sectional thickness of the construct to
determine an appropriate diffusion distance for any compound. This distance will inherently
be involved in the transport rates of any compound across a cultured membrane. In such a
BBB model, which tests for permeability, it would be necessary to take into account the
thicknesses of the ECs, the astrocytes, and the thickness of the transwell membrane. SEM
imaging has shown cell diameter ranging from 5-13 µm for Endothelial cells67 and 2.3 µm for
C6 cells68. After taking into account the 10 µm thickness of the transwell insert membrane, it
is possible to include the 17-23 µm distance through which a compound must diffuse into any
calculations regarding transport rates.
Section 1.6

Modeling the Blood-Brain Barrier

Typical methods for modeling the BBB include in-silico (or computer-aided) models,
static mono- and co-cultures, and dynamic or flow-associated mono- and co-cultures69. As of
now, the most cost-effective method of modeling the BBB properties is the use of computeraided design (CAD) modeling69. This type of modeling employs solid models that mimic the
physiologic properties of the blood vessels, which help form the BBB. Through the
incorporation of permeability values typical in-vivo, it is possible to simulate a compounds
interaction with a biologic system. These models allow for pre-screening of a larger volume of
potential drug candidates though the prediction of their permeability coefficients. It is
necessary, however, to incorporate standard physiological parameters (e.g. solubility,
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lipophilicity, molecular size, capacity for hydrogen bonding, and charge distribution) into the
simulation to obtain usable data70. These criterion are established through animal testing data,
wherein small animals (typically rodents) are injected with a compound, euthanized, and their
brains histologically examined for drug concentration values39. This standardized
measurement, referred to as the “LogBB” value, equates the concentration of the compound
within the brain to the concentration found in the blood plasma71,72. While this type of
experimentation provides useful and necessary toxicological data, much research on the BBB
is focused on the development of an in-vitro system that would bridge this gap between the
computer modeling and preclinical animal screening.
The most common technique for establishing an experimental BBB model in-vitro
includes the use of monocultures of brain microvessel endothelial cells (human or animal,
typically bovine) or co-cultures of endothelial cells and astrocytes73. The monoculture
approach provides data indicating a downregulation of complete tight junction characteristics
in the absence of astrocytic influence. By including a single cell type (ECs) onto a porous
transwell insert, it is possible to test membrane permeability with multiple drug compounds in
the same well or varying concentrations of the same drug across different wells69. While
solely providing a cursory examination of the limited expression of BBB properties in a
monoculture of ECs, this type of model can be induced to express slightly enhanced BBB
characteristics through the introduction of astrocyte or glia media (or alternatively, in a serumfree medium with the introduction of hydrocortisone)74-77. The absence of natural stimuli such
as astrocyte-EC interaction and physiologic flow conditions results in down-regulation of
tight-junction associated proteins, and necessitates the use of a more relevant model18,78.
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The preferred co-culture method demonstrates enhanced tight junctional protein
expression and increased Transendothelial Electrical Resistance (TEER) values by taking into
account the necessary interaction between the endothelium and the astrocyte endfeet
processes79. Co-culture of these two cell types often utilizes porous transwell inserts that
simulate the separation of the astrocytes and the endothelial cells observed in vivo by the
basement membrane, while allowing for the astrocytic endfeet to extend through the
micropores and interact with the ECs. This separation and interaction facilitate enhanced
development of BBB characteristics27,80,81. While this model introduces the intercellular
communication between the endothelial cells and astrocytes that is necessary for proper
barrier formation, the lack of shear stress on the apical membrane of the ECs results in
diminished TEER values, effectively increasing the membrane permeability coefficient69.
Therefore, it is desirable to develop a dynamic in-vitro model.
These tri-dimensional models involving the co-culture of astrocytes and ECs along
with exposure to flow, referred to as dynamic in-vitro blood-brain barrier (DIV-BBB) models,
result in enhanced tight junctional protein expression along with physiologically relevant
TEER values. The majority of these models utilize a tubular hollow fiber scaffold with
intraluminally seeded endothelial cells and extraluminally seeded astrocytes69. With the
incorporation of pulsatile changes in flow and shear stresses through the lumen of the hollow
fibers, and a physiologically relevant pressure drop from inlet to outlet, the endothelium takes
on a morphology that more closely resembles the in-vivo situation82. However, the use of
these (typically polypropylene) hollow fibers limits the ability for intraluminal observation,
restricting the examination of changes in morphometry and endothelial cell phenotype.
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Section 1.6.1 Custom DIV-BBB Models
There are few commercial perfusion bioreactor systems for BBB research. However,
all of the options available incorporate the use of hollow fibers into their bioreactor. These
hollow fiber setups are widely used in BBB experimentation23,83-85, as they mimic the
capillary bed where the barrier is formed in-vivo. These fibers allow for intraluminal seeding
of endothelial cells and extraluminal seeding of astrocytes. The permeable polypropylene
fibers then allow for nutrient exchange between the lumen and extracellular media.
Experimentation that includes these hollow fibers involve typically involves the use of
endothelial cells and glial cells, often BAECs23,26 and C6s 23,26,83,86. Flow conditions through
each of the fibers is calculated to fall within typical BBB ranges (1-2 dynes/cm2)82, and
systems are cultured according to typical cell culture protocol (37°C, 5% CO2, etc.). Most
hollow fiber bioreactor modules will disperse fluid flow through around 50 of these fibers,
allowing for a pressure and shear stress drop typical of a capillary bed. Across this artificial
vascular bed, these hollow fiber models of the BBB are also able to provide information on
the permeability of certain compounds through the barrier, as well as indications of transport
protein function.
However, there are some significant drawbacks to the use of hollow fiber cartridges.
IF staining and histological sectioning is typically performed on any scaffold containing cells
to determine presence, viability, location, and confluency of the cells. In the case of a hollow
fiber bioreactor assembly, this means that the one time use housing must be cut open with a
band saw and the individual fibers placed in fixative. Once fixed, the polypropylene fibers
become brittle, and exposure of the lumen becomes difficult. This results in issues
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surrounding whole mount imaging on a fluorescence microscope, or even histological
sectioning with typical paraffin embedding.
These commercial systems represent the first attempt to satisfy the demand for a
practical, easy to use DIV-BBB model. Further investigations into the characterization of a
BBB model that could facilitate drug development and toxicological screening will require
incorporation of reusable bioreactor components. Additionally, the use of a robust scaffolding
material that is easy to stain and section in addition to providing dynamic permeability data
will provide a simple and inexpensive method of examining the BBB in a bench top model.
Section 1.6.2 Current State of BBB Research in the Tissue Engineering Lab
BBB research in the Tissue Engineering Lab at Cal Poly, initially started by Bryan
Brandon, and subsequently followed by several others87-89, has set the initial foundation for
exploring the formation of tight junctions and proper barrier functionality both in static and
dynamic culture conditions87. BAECs and C6s were carefully selected for the BBB model,
and initial studies involved the development of a protocol for culturing both of these cell
types. The CellMax DUO hollow fiber perfusion bioreactor system was initially chosen as the
system to model the BBB (Figure 6). This hollow fiber system was then characterized in
terms of the flow rates and shear stresses inside the fibers as they are related to the channel
settings on the system. A protocol for sodding the hollow fiber system with BAECs only was
then developed.
This previous experimentation established the necessary protocols for culturing both
of the cell types crucial to formation of the BBB. These protocols, along with initial
experimentation into seeding the BAECs into a dynamic model of the BBB, have helped to
establish a working knowledge of how to manage these cell types and how to manipulate them
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in a culture setting (both static and dynamic) to change the expression of the elements forming
the barrier.
In addition, the previous research in this lab has shown the difficulties associated with
the use of a commercial hollow fiber bioreactor as a model for the BBB. Issues arising from
opening the bioreactor and subsequent imaging of the fibers indicate the need for the
development of an in-house custom bioreactor system. This system should account for the
shortcomings of these hollow fiber systems, in that it needs to be reusable and incorporate a
scaffolding material that is easy to section and stain, while allowing co-culture of the two key
cell types in a dynamic environment.

Figure 6| CellMax hollow fiber bioreactor system previously used in the Tissue Engineering
Lab at Cal Poly for BBB Research.
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Section 1.7

Summary and Aims of the Thesis

The BBB protects our CNS from potentially toxic compounds by selectively screening
which molecules can diffuse from the circulatory system into the microenvironment in the
brain. In the design of any drug compound, it is therefore necessary to both understand the
physiology and functional characteristics of the BBB and to be able to model the barrier in an
in-vitro setting. This research surrounding the BBB plays a critical role in both the
development of novel methods to model the barrier for toxicological screening and in the
development of methods for acute modulation of BBB permeability for treatment of CNS
disorders.
The expression of tight junctional proteins and formation of the BBB has been
established in static culture conditions26,90, and the use of hollow fiber bioreactors has enabled
the modeling of the BBB in a dynamic environment23,83,91. While the majority of academia
uses these hollow fiber systems, the issues regarding opening the bioreactor and imaging the
fibers in addition to the high costs associated with repeated purchase of hollow fiber modules
necessitates the development of a reusable and easy to use perfusion bioreactor system for
ongoing work at Cal Poly.
To account for shortcomings related to ease of culture and ease of data collection of
most commercially available perfusion bioreactor systems, including the one in the Cal Poly
Tissue Engineering lab, current in-vitro BBB research in academia is focused on the
construction of new dynamic BBB models that allow for assessment of cellular architecture at
different time points, histological examination, and the induction of native blood vessel
pressures (1-2 dynes/cm2 for BBB capillaries) in addition to the potential for permeability
screening of new drug compounds.
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The experiments conducted in this thesis examine the interaction between BAECs and
C6 cells in mono- and co-cultures along with permeability data using transwell inserts. This
data will lay the groundwork for full perfusion bioreactor setups, involving the sodding of the
ECs and glial cells into a poly(lactic-co-glycolic acid) (PLGA) tubular scaffold in a novel
perfusion bioreactor system. Such a system would allow for the cultivation of ECs and glial
cells on a tubular scaffold inside of a custom designed bioreactor, and would facilitate the
simultaneous cultivation of four vascular constructs, while administering native hemodynamic
conditions. Additionally, the use of a PLGA scaffold will support post-experimental analysis
through cryosectioning and immunohistochemical (IF) staining.
The overall goal of current work at Cal Poly is to develop an in-house dynamic model
of the BBB that would facilitate the investigation of transport across a cellular monolayer.
One aspect of this overall goal will be to successfully culture and assess the proper cell types.
Therefore, the focus of this project is to develop a protocol to determine expression of BBB
tight junctional proteins in culture, and to assess permeability of the cell monolayer. This
project will therefore have two aims. The first aim is to develop a protocol to determine the
presence of tight junctional proteins. An IF stain will be developed to label each cell surface
protein with a fluorescent antibody. In imaging these groups, it will be possible to obtain data
regarding baseline expression of tight junctional proteins, and also data regarding the change
in expression of these proteins in response to external stimuli (including introduction to
astrocytes). This protocol will provide the tools necessary to determine the location of protein
expression as well as information regarding the extent of BBB formation.
The second aim of this project is to assess the permeability values associated with a
co-culture model of astrocytes and ECs. This will be performed using transwell inserts, on
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which glial cells will be cultured in the lower compartment, and ECs in the upper
compartment. This will establish a dual-layer of cells, through which the permeability of
known compounds can be tested. This aim will provide a functional assessment of the BBB
formation, and provide the platform for scaling up the model to a perfusion-based system.
The completion of Aims 1 and 2 will provide the foundation for dual-sod setups of
BAECs and C6s in an in-house custom perfusion bioreactor system. This perfusion system
will not only mimic the functional characteristics of the BBB found in-vivo, but will also
provide a BBB model that is easy to use and reuse, simple to analyze and perform histological
analysis on, and provide a practical alternative to in-vivo permeability testing.
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Chapter 2 – Immunofluorescence Protocol Development for Tight Junctional Proteins

Section 2.0

Introduction

The development of an Immunofluorescence (IF) protocol for tight junctional protein
staining was necessary to determine the extent to which the BBB formed in an in-vitro model.
The key junctional proteins that were investigated using this protocol included ZO-1 and
Claudin-5, which are tight junction specific proteins, and PECAM-1, which is a standard
endothelial cell marker. This protocol included the use of primary antibodies (specific to each
of the tight junctional proteins listed above) and fluorescent secondary antibodies. The use of
a non-fluorescent primary and a fluorescent secondary antibody enabled the labeling and
imaging of the ZO-1, Claudin-5, and PECAM-1 proteins. Evaluation of the expression of
these proteins provided insight into the extent of formation of tight junctions in our in-vitro
model.
The previous protocol for immunohistological staining, henceforth referred to as IF
Protocol version 1, was developed by T.J Eames and used for initial staining of tight junctionspecific cell surface proteins (Appendix 2.0). Due to issues arising from the use of this
protocol, the first few attempts at staining endothelial cells resulted in non-usable images.
Therefore, the majority of this protocol was replaced with steps from a separate IF protocol,
hereby referred to as IF Protocol version 2. This protocol allowed for staining of PECAM-1
on endothelial cells, and had previously been used by Marcus Foley and Elizabeth Curiel in
the Tissue Engineering Lab at Cal Poly (Appendix 2.1). While this protocol resulted in usable
fluorescent images, it had been tailored to stain for PECAM-1 on endothelial cells obtained
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from human umbilical veins (hUVECs), and therefore demanded further investigation into its
potential use in tight junctional protein staining.
Section 2.1

Methods

The endothelial cells used in this research were sourced from the bovine aorta (Lonza,
Cat. No. BW-6002). To determine formation of BBB specific tight junctional proteins, the
Zona Occludens-1 (ZO-1) protein was chosen as the principle target for IF staining, and the
appropriate primary antibody (Rabbit Anti-ZO-1) was purchased (Invitrogen, Cat. No. 617300), along with a fluorescently labeled secondary antibody (Alexa Fluor 488 Donkey AntiRabbit, Invitrogen, Cat. No. A21206). This chapter outlines the use of both the primary and
secondary ZO-1 antibodies to evaluate and modify the IF protocol version 1. Once the initial
modifications to version 1 of the protocol had been made, primary and secondary antibodies
for Claudin-5 (Invitrogen, Cat. No. 341600) and PECAM-1 (Invitrogen, Cat. No. 37-0700)
were incorporated to obtain a more broad understanding of tight junctional protein expression
and endothelial cell phenotype retention.
Experimentation with the IF protocol began with the initial modification of protocol
version 1 (used by T.J. Eames) to incorporate the steps outlined in the protocol used by
Marcus Foley and Elizabeth Curiel, termed IF protocol version 2. IF protocol version 2 was
then used to determine changes in ZO-1 expression as a function of changes in monolayer
confluency, and as a function of endothelial cell and glial cell co-culture. When the use of IF
protocol version 2 resulted in the nonspecific binding of the ZO-1, Claudin-5, and PECAM-1
antibodies to the glial cells, the protocol was again modified to IF protocol version 3.
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Section 2.1.1 Study 1 - Modification to IF Protocol Version 1
In this experiment, it was necessary to modify IF protocol version 1, and to validate
the use of IF protocol version 2 as a means for labeling the ZO-1 protein. The initial changes
to IF protocol version 1 included the use of Formalin as opposed to Paraformaldehyde as a
fixative, a less concentrated solution of Triton X-100 for permeabilization, the use of Bovine
Serum Albumin as a blocking buffer, and changes to the primary and secondary antibody
dilution. These changes were in accordance with the protocol established for PECAM-1
staining of hUVECs (Appendix 2.1). Once the IF protocol version 1 had been modified to the
IF protocol version 2 (Appendix 2.2), an IF stain was performed to ensure proper labeling of
the ZO-1 protein. Because this protocol was modeled after the protocol listed in Appendix 2.1,
hUVECs were stained and used as a comparison group, in addition to the BAECs of interest.
To validate the use of IF protocol 2 as a means of labeling the ZO-1 protein, P12
BAECs and P10 hUVECs were cultured to confluency according to the protocol in (Appendix
2.3) on coverslips (Fischer Science, Cat. No. 22CIR-1D) inside of 6-well plates (VWR
International, Inc., Cat. No. 3506) and stained using the IF protocol (Appendix 2.2) as shown
in Figure 7. Once ready, these coverslips were transferred to a glass slide, and placed on an
Olympus BX41 Widefield Fluorescence Microscope (Figure 8). The filter wheel settings and
turret positions for the microscope are listed in Table 1. The capture settings used were 100ms
exposure for Bisbenzimide (BBI) and 1s 999ms exposure for the secondary antibody.
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Figure 7| 6-well plate setups showing cell type and treatment group for IF stain for ZO-1.

Table 1| Filter Wheel Setting for the Widefield Fluorescent Microscope. Filter Wheel and
Turret Positions are listed for BBI and IF staining.
BBI Secondary Antibody
Filter Wheel 1
1
6
Filter Wheel 2
1
5
Turret Position 4
2

Figure 8| Olympus BX41 Widefield Fluorescence Microscope. Turret is located directly
above the stage and below the eyepieces. Filter wheel positions are controlled using the pad in
the lower right corner.
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The fluorescent images obtained from this experiment are shown below in Figure 9.
Experimental groups for this experiment include administration of both the primary and
secondary antibodies, while the negative control groups consisted of administration of only
the secondary antibody. This ensured that the secondary antibody is only binding to primary
antibody. The images obtained show comparable antibody staining in both the BAECs and the
hUVECs, which suggested that it was appropriate to use IF protocol version 2 for tight
junctional protein labeling. Having determined that IF protocol version 2 was practical for
tagging the ZO-1 protein on BAECs, it was then possible to investigate the changes in ZO-1
expression as function of monolayer confluency and as a function of EC and astrocyte coculture.
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Figure 9| Images from IF stain performed on BAECs and HUVECs. Primary+Secondary
Antibody groups (A and E) are positive for ZO-1 expression. The negative control groups (C
and G) are negative for ZO-1 expression, indicating a lack of nonspecific binding of the
antibody. Composite images (D and H) indicate ZO-1 expression localized to the nuclei, seen
in the BBI images B and F.
Section 2.1.2 Study 2 - ZO-1 Expression as a function of Confluency
Once the IF protocol version 2 had been verified for primary and secondary antibody
labeling of the ZO-1 protein on BAECs, it was necessary to determine if there was
upregulation in the expression of this protein when the endothelial cells were more confluent.
This increase in ZO-1 protein expression was to be determined through monoculture of
BAECs in 6-well plates. Each of the wells in these plates contained a different concentration
of cells, therefore allowing imaging and qualitative analysis of the extent to which ZO-1 was
being expressed as a function of monolayer confluency.
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Section 2.1.2.1

Confluency Experiment 1

In this experiment, P5 BAECs were cultured in 2 T225 flasks according to the protocol
in (Appendix 2.3). These cells were then trypsinized, and resuspended in 20 ml of BAEC
media. This media was then pipetted into 2 6-well plates in the configuration shown in Figure
10. By pipetting varying volumes of cell suspended media, increasing concentrations of
BAECs were plated into the 6-well plates. These differences in concentration would facilitate
the culture of monolayers varying in confluency.
White light analysis of the cells preceding the IF stain confirmed increasing
confluency of the BAECs (Figure 11). The cells were then stained according to IF protocol
version 2 and imaged using the Widefield Fluorescent Microscope. However, issues arising
from a faulty pipette aid resulted in non-usable fluorescent images for ZO-1. These images,
shown in Figure 11, show not only a lack of primary and secondary antibody staining, but also
a lack of stained nuclei from the BBI. This indicated that the stains used weren’t necessarily at
fault, but the instrumentation used to administer the stains was not functioning correctly.
Therefore, this same experiment was repeated, taking care to ensure that the primary and
secondary ZO-1 antibodies were appropriately introduced to each experimental group.

Figure 10| Distribution of BAECs in two 6-well plates. BAECs were suspended in 20 ml of
media and distributed to the positive and negative control groups at a concentration of 5.46E4
cells/cm2.
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Figure 11| Results from ZO-1 expression as a function of Confluency experiment. The white
light images (A, D, G, J) show increasing confluency as the concentration of cells increases
from 1ml to 4ml. IF and BBI staining (middle and right columns) did not work.
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Section 2.1.2.2

Confluency Experiment 2

In this study, a second experiment was setup similar to Confluency Experiment 1. P4
BAECs were cultured according to the protocol in (Appendix 2.3) in 1 T225 flask,
trypsinized, suspended in 20 ml of media and pipetted into 6-well plates as shown in (Figure
10). Following a 24-hour time period, the coverslips were imaged on a glass slide under the
Widefield Fluorescence Microscope using the settings shown in Table 1.
The white light images shown in Figure 12 indicate increasing monolayer confluency
as the concentration of BAECs in the 6-well plate increased. Fluorescent imaging also shown
in Figure 12 revealed a qualitative increase in ZO-1 expression in the BAECs as the cells
became more confluent. The negative control groups consisting of the secondary antibody
only, showed no fluorescent staining indicating a lack of nonspecific binding of the primary
antibody. Once these changes in ZO-1 expression as a function of monolayer confluency had
been verified using IF protocol version 2, it was necessary to evaluate similar changes in ZO1 expression as a function of EC and astrocyte co-culture.
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Figure 12| Results from second ZO-1 expression as a function of Confluency experiment. The
white light images (A, D, G, J) and BBI images (D, H, L, P) show increasing confluency as
the concentration of cells increases from 5.32E4 to 2.14E5 cells/cm2. IF staining (B, F, J, N)
was positive in all groups, and control groups (C, G, K, O) were negative for ZO-1
expression.
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Section 2.1.3 Study 3 - ZO-1 Expression as a Function of BAEC and C6 Co-Culture
This experiment investigated the change in ZO-1 expression due to astrocytic
influences on endothelial cells in a co-culture setup. The upregulation of tight junction
associated cell surface proteins located on endothelial cells has been supported in co-culture
situations involving endothelial cells and astrocytes27. At this point in the protocol
development, IF stains using IF protocol version 2 have shown positive ZO-1 stains on
endothelial cells. The upregulation in the expression of this protein as a function of monolayer
confluency has also been established utilizing the current protocol. Because changes in the
expression of ZO-1 have been established in endothelial cell-only culture conditions, it is
necessary to examine the expression of this protein when the endothelial cells are exposed to
astrocytic influences.
The astrocytic cell lines used were rat glioma cells (ATCC, Cat. No. CCL-107). To
understand the way with which these cells interact with endothelial cells, it was necessary to
investigate each possible orientation during culture. This includes BAECs grown on top of
C6s, C6s grown on top of BAECs, and a mixture of the two cell types. Tracking of the
location and possible migration each cell type was assessed using Cell Tracker (CT) Dye
(Invitrogen, Cat. No. C34552 and Cat. No. C10094). This is a fluorescent nuclear stain, which
is incorporated into daughter cells, and enables labeling of an entire colony.
Section 2.1.3.1

Co-Culture Study 1 - BAECs/C6s

This first co-culture experiment consisted of BAECs grown on top of a monolayer of
C6 cells, shown in Figure 13. Three vials of P7 BAECs and P12 C6s were cultured according
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to the protocol in (Appendix 2.3). Once confluent, BAECs were stained using Cell Tracker
Violet, while the C6s were stained using Cell Tracker Red.
Once stained, the C6s were trypsinized and pipetted into their corresponding wells
(Figure 14) at a concentration of 3.34E5 cells/cm2, and allowed to culture for 24 hours. The
BAECs were then trypsinized and pipetted in their corresponding wells at a concentration of
8.89E6 cells/ml and 1 ml per well. The concentrations used in this setup were to mimic the
ratio of BAECs to C6s (1:3) that is typically found in-vivo21.

Figure 13| Orientation of both cell types in co-culture. BAECs were grown on top of C6s,
which were cultured on coverslips inside a well of a 6-well plate. Eye indicates direction from
which each sample was imaged using the Widefield Fluorescent Microscope.

Figure 14| Location of each experimental group for IF stain for ZO-1. This experiment
investigated the expression of ZO-1 when BAECs and C6s are co-cultured (BAECs grown on
top of C6 cells).
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Initial white light analysis (Figure 15) showed a change in endothelial cell morphology
in the co-culture groups. Additionally, formation of large clusters of cells in the co-culture
and C6 only groups indicated a lack of monolayer formation. Because of this, further IF
staining was not possible. Both the formation of these cell clusters and the lack of cellular
adherence in a confluent monolayer to the 6-well plates suggest issues regarding the plating
of BAECs on top of C6s. Therefore, the following co-culture experiment investigated
changes in ZO-1 expression in response to astrocytic influences, when C6s were plated on
top of BAECs.

Figure 15| White light images of (A) BAECs only, (B) C6s only, and (C) BAECs cultured on
top of C6s. B and C show the low level of adherence to the cell culture flask, and the
congregations of cell into groups.
Section 2.1.3.2

Co-Culture Study 2 - C6s/BAECs

This experiment investigated the changes in ZO-1 expression as a function of C6 cells
cultured on top of BAECs. Initial experimentation growing BAECs on top of C6 cells
revealed issues relating to the surface tenacity of either the BAECs to the C6s, or of the C6s to
the cell culture flask. Specifically, the C6 cells were unable to adequately adhere to the
coverslips when BAECs were cultured on top of the astrocytes. Therefore, subsequent
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experimentation investigated a different co-culture orientation to hopefully account for issues
with cell adherence.
Similar to the first experiment, this study investigated upregulation of tight junctional
proteins in co-culture of C6 cells grown on top of BAECs (Figure 16). P6 BAECs and P9 C6s
were cultured according to the protocol in (Appendix 2.3). P6 BAECs were passed 1:3 into a
T225 flask according to the protocol in (Appendix 2.3). Once Confluent, Cell Tracker dye was
again used to label each cell type, BAECs with CT Red and C6s with CT Violet.
Once labeled with Cell Tracker, BAECs were trypsinized and pipetted into their
corresponding wells (Figure 17) and allowed to culture for 24 hours. C6 cells were then
trypsinized and added to the remaining wells. The positive control group was labeled with the

Figure 16| Orientation of both cell types in co-culture. C6s were grown on top of BAECs,
which were cultured on coverslips inside a well of a 6-well plate. Eye indicates direction from
which each samples was imaged using the Widefield Fluorescent Microscope.

Figure 17| Location of each experimental group for IF stain for ZO-1. This experiment
investigated the expression of ZO-1 when BAECs and C6s are co-cultured (C6s grown on top
of BAECs).
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ZO-1 primary and secondary antibody, while the negative control group was only
labeled with the secondary antibody (to test for nonspecific binding of the fluorescent
secondary).
All experimental groups, including the C6 only group, stained positive for tight
junction specific ZO-1 protein (Figure 18). The negative control showed no antibody staining,
suggesting a lack of nonspecific binding of the secondary antibody. Location of BAEC and
C6 nuclei can be seen in the BBI images, but issues with the CT dye (labeling
C6 cells) made it difficult to distinguish between both cell types. The problems with imaging
the CT dye were due to light reflecting off of the ceiling and down through the eyepiece, and
were accounted for in future stains.
Due to the positive staining observed in the C6 group, it was necessary to determine
whether this observed fluorescence was due to nonspecific binding of the ZO-1 primary
antibody on the astrocytes, or if this labeling was due to the ZO-1 protein being expressed on
the astrocytes92. Therefore, the following experiment involved staining for ZO-1, Claudin-5,
and PECAM-1 on the ECs and astrocytes both in mono- and co-culture groups to determine if
the target proteins for the Claudin-5 and PECAM-1 antibodies were present on the C6 cells.
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Figure 18| IF stain for co-culture experiment. Primary+Secondary staining (A, E, I) is
positive for ZO-1 expression. Negative control groups (D, H, L) are negative for ZO-1
expression, indicating a lack of nonspecific antibody binding. CT Violet images (C, G, K)
indicate C6 cells, while BBI images (B, F, J) indicate location of both cell types.
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Section 2.2

Study 4 - IF stain for ZO-1, Claudin-5, and PECAM1 on EC and C6

mono- and co-culture groups
In this experiment, it was necessary to determine if the positive ZO-1 staining
observed in the C6 only group was due to nonspecific binding of the ZO-1 antibody, or if
there is ZO-1 protein expression on the astrocytes. Therefore, this study involved the
simultaneous staining for ZO-1, Claudin-5, and PECAM-1 on ECs and Astrocytes in monoand co-culture groups to evaluate if there was also positive Claudin-5 and PECAM-1 staining
in the C6 groups. Initially, this experiment was performed using the IF protocol version 2,
which was programmed into a DAKO Autostainer. As the use of the autostainer proved
unsuccessful as shown in Appendix 2.4, resulting in unusable slides, the same experimental
setup was established, and each experimental group was stained by hand according to IF
protocol version 2.
The following co-culture test included the same experimental setup as established for
the autostainer experiment as listed in Appendix 2.4, however the IF stain was performed by
hand. One vial of P6 and P8 BAECs along with 3 vials of P9 C6s were cultured according to
the protocol in the (Appendix 2.3). The BAECs were trypsinized and plated onto their
respective glass slides inside of 6-well plates for the BAEC only and C6/BAEC groups.
Similarly, the C6s were trypsinized and placed into their respective wells for the C6 only and
BAEC/C6 groups. After allowing each group of cells to adhere to the coverslips inside of the
well for 24 hours, half of the remaining BAECs and C6s were trypsinized and plated onto the
BAEC/C6 and C6/BAEC groups, respectively. The second half of the remaining BAECs and
C6s were mixed together and placed into their respective wells. The protocol for establishing
these experimental groups is available in Appendix 2.6, and the location of each of these
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groups is shown in Figure 19. All 48 slides were stained using IF protocol version 2 and
imaged on the Multiphoton Laser Scanning Microscope using the 40x oil objective.

Figure 19| Location of each experimental group for IF stain for ZO-1, PECAM-1, and
Claudin-5. This experiment investigated the expression of these three cell surface proteins
when BAECs and C6s are co-cultured (BAECs grown on top of C6 cells, C6s grown on top of
BAECs, and a mixture of the two cell types).
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Graphs of the brightness values for each of these experimental groups can be found in
(Appendix 2.7). Again, the C6 only groups were positive not only for ZO-1, but also exhibited
fluorescence for the Claudin-5 and PECAM-1 antibodies, suggesting that there were most
likely issues with the primary antibody binding to areas of the cell other than its intended
protein target. Therefore, investigations into alternative blocking buffers were necessary to
ensure that the IF protocol is allowing for accurate and specific protein labeling.
Section 2.3

Study 5 - Blocking Buffer Experimentation

To account for the issues associated with nonspecific binding resulting in labeling of
tight junctional proteins on C6 cells, three different blocking buffers were compared. This
version of the IF protocol, IF protocol version 3 shown in Appendix 2.8, included the use of
Bovine Serum Albumin (BSA) (Invitrogen, Cat. No. 15561-020), 10% Normal Goat Serum
(NGS) (Invitrogen, Cat. No. 50-197Z), or Normal Donkey Serum (NDS) (Calbiochem, Cat.
No. 655460) as substitutions for the previous blocking buffer used in IF protocol version2. IF
protocol version 3 was then applied to the experimental groups as shown in Figure 19.
Section 2.3.1 Claudin-5 stain on C6s alone
To determine the correct blocking buffer to incorporate into the IF staining protocol,
BSA, NGS, and NDS were used to block for nonspecific binding on C6 cells. P12 C6s were
cultured according to the protocol in (Appendix 2.3) and stained according to Figure 20. The
BSA groups were positive for Claudin-5 expression on C6s, while both the NGS and NDS
groups did not show any fluorescent labeling (Figure 21). As there was some observable
fluorescence in the NGS group, NDS replaced BSA as the blocking buffer in the IF protocol
version 3.
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Figure 20| Location of each of the positive and negative control groups in the blocking buffer
experiment using C6 cells.

Figure 21| IF stain on C6 cells using three different blocking buffers: BSA, NGS, and NDS.
Primary+Secondary antibody images (A, E, I) indicate positive ZO-1 expression in BSA
group, and negative expression in NGS and NDS groups. Negative control groups (C, G, K)
indicate a lack of nonspecific binding of the antibody. Cell nuclei locations are seen in BBI
images (B, F, J), and composite images (D, H, L) indicate protein expression localized to cell
membranes.
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Section 2.3.2 Final Proof of Concept IF Stain
Finally, it was necessary to test the final IF protocol version 3 (Appendix 2.8) on a set
of experimental groups including BAECs alone, C6s alone, and a group of BAECs mixed
with C6s. This ensured that the protocol would stain for tight junctional-specific proteins only,
while disallowing for nonspecific binding of the primary antibody. P9 BAECs and P12 C6s
were cultured according to the protocol in Appendix 2.3. Once reaching confluency, the cells
were placed in their respective wells (Figure 22) and stained using the protocol in Appendix
2.6 and imaged on the Multiphoton Laser Scanning Microscope.
The BAEC only group stained positive for Claudin-5 expression, while the C6 only
group did not express Claudin-5, suggesting that NDS was sufficient to block for nonspecific
binding of the primary antibody (Figure 23). Additionally, the Mix group qualitatively
showed an increase in brightness for the Claudin-5 antibody. The negative control group
supported the lack of nonspecific binding of the secondary antibody.

Figure 22| Location of each of the positive and negative control groups in the final IF staining
experiment using monocultures and co-cultures of BAECs and C6s.
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Figure 23| IF stain showing Claudin-5 stain of BAECs only (A-D), C6s only (E-H), and Mix
groups (I-L). Primary+Secondary antibody groups (A, E, I) show positive Claudin-5
expression in BAEC and Mix groups, and negative expression in the C6 group. The negative
control groups (C, G, K) indicate a lack of nonspecific binding of the antibody. Cell nuclei
location can be seen in the BBI images (B, F, J), and the composite images (D, H, L) indicate
localization of protein expression to each cell membrane.
This data suggests that the following IF protocol for tight junctional protein staining is
appropriate to provide specific protein labeling while inhibiting nonspecific binding of either
the primary or the secondary antibody.
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Final IF Protocol for Tight Junctional Protein Staining
1. Remove cell culture media and fix cells in 10% Formalin for 15 minutes.
2. 3x PBS washes for 5 minutes each.
3. Permeabilize cells in 0.2% Triton X-100
4. 3x PBS washes for 5 minutes each.
5. Block for non-specific binding using 3% Normal Donkey Serum (NDS)
6. Incubate in Primary Antibody and 3% NDS for 24 hours.
7. 3x PBS washes for 5 minutes each.
** Steps 8-12 are LIGHT SENSITIVE**
8. Incubate in secondary antibody and 3% NDS for 50 minutes.
9. 3x PBS washes for 5 minutes each.
10. Counter stain using Bisbenzimide for 15 minutes.
11. 1x PBS wash for 5 minutes.
12. Remove coverslips from each well, mount to glass slides using mounting medium, and
allow to dry for 24 hours.
Section 2.4

Results and Discussion

This chapter focused on the development of a protocol for immunohistochemical
staining of tight junctional proteins on endothelial cells. This included investigations into the
expression of these proteins as a function of confluency, and also as a function co-culture with
glial cells. Completion of this first aim has resulted in establishment of a robust protocol for
IF staining of endothelial cells for the ZO-1, Claudin-5, and PECAM-1 proteins. Use of this
protocol in our lab is critical to the development of our working knowledge of static and
dynamic BBB modeling.
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IF protocol version 1 was modified with elements from a similar protocol for primary
and secondary antibody labeling of PECAM-1 on hUVECs. This hybrid staining protocol, IF
protocol version 2, was then tested by staining for ZO-1 on BAECs and hUVECs. Positive
ZO-1 expression and usable images on the fluorescent microscope supported the further use of
this protocol in staining for tight junctional proteins.
The next set of experiments involved the use of IF protocol version 2 to determine the
expression of ZO-1 as a function of endothelial cell confluency. Evaluations of the results
from this study revealed an increase in the relative brightness of each image (positively
correlated with protein expression). Because IF protocol version 2 was able to stain for these
proteins and support the increase in protein expression as a function of confluency, it was then
necessary to determine changes in ZO-1 expression in the presence of glial cells. It is also
important to note, that the use of IF protocol version 2 in this experiment did result in
fluorescence observed in the C6 only group, suggesting either nonspecific binding, or the
expression of ZO-1 on the C6 cells. Because the presence of the ZO-1 protein has been
described in astroctyes92, it was necessary to determine if the observed fluorescence was in
fact due to nonspecific binding. Therefore, the following set of experiments involved the use
of Claudin-5 and PECAM-1 primary antibodies in addition to the ZO-1 antibody, to determine
if Clauin-5 and PECAM-1 were also being labeled on the C6 cells.
The next set of experiments involved IF staining of co-cultures of BAECs and C6 cells
again using IF protocol version 2. These investigations were to determine how glial cells
interact with endothelial cells to change the expression of certain tight junctional proteins, and
to determine if Claudin-5 and PECAM-1 were also being labeled on the C6 cells. Specifically,
these experimental groups were stained for ZO-1, PECAM-1, and Claudin-5 proteins. IF
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protocol version 2 was used in these tests to determine changes in the relative brightness (or
expression of these tight junctional proteins) when glial cells interact with the endothelial
cells.
Each group was manually stained with either primary+secondary or secondary only for
ZO-1, PECAM-1, and Claudin-5. These groups were then mounted onto glass slides and
imaged using the multiphoton laser scanning microscope. All of the groups stained for ZO-1
showed statistically significant increases in brightness over the negative control groups,
indicating successful inhibition of nonspecific binding of the secondary antibody.
Additionally, the BAEC on top of C6 group showed a statistically significant increase in
brightness over the BAEC only group. Although not statistically significant, there was an
overall trend toward increases in brightness in the co-culture groups.
Groups stained for Claudin-5 exhibited similar characteristics. Statistically significant
differences were observed between the positive and negative control groups, indicating a lack
of nonspecific binding of the secondary antibody. There was a general trend toward the coculture groups showing an increase in brightness. However, the only statistical differences
were between the BAEC on top of C6 and the C6 on top of BAEC groups and the BAEC only
group.
The final treatment group, stained for PECAM-1, also showed a statistically
significant difference between the positive and negative control groups. However, there was
no statistical significance in brightness between any of the experimental groups. The data did
not even reveal a general trend of changes in protein expression. These results are to be
expected, as PECAM-1 is solely an endothelial cell marker. As it is not a tight junctional
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protein specific to BBB formation, we should expect to see no changes in brightness as a
function of co-culture with glial cells.
The Cell Tracker data for each of the experimental groups revealed little to no
migration of the cells types between monolayers. This suggests that tight junction formation is
not dependent upon the orientation of the cell types in co-culture. However, in each
experimental group and in each antibody stain, it was observed that there was a trend toward a
decreased brightness in the Mix group. This could suggest that while the orientation of the
two cell types in not important, it is important to keep to the two cell types in their distinct
monolayers during co-culture.
Overall, the confocal images collected from this experiment indicate an upregulation
in tight junctional protein fluorescence when BAECs and C6 cells are co-cultured.
Quantitative data regarding differences between the experimental and control groups from this
study can be found in Appendix 2.7. This study also revealed that IF protocol version 2 was
allowing for nonspecific binding of the primary antibody, effectively invalidating all of the
previous results.
Due to the failure of IF protocol version 2 to provide accurate and reliable tight
junctional protein staining, it is important to reevaluate the interpretations of the previous
studies. While the confluency study suggested that there is an increase in ZO-1 expression as
the cell monolayer becomes more confluent, this observed increase in fluorescence could also
be the result of increased nonspecific binding. Likewise, the trends observed in the final coculture experiment describing an increase in tight junctional protein expression when ECs and
astrocytes are co-cultured could also be a direct result of increased opportunity for nonspecific
binding. Due to the presence of two cell types in culture, there is potentially twice the
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opportunity for the primary antibody to nonspecifically bind to areas of both the BAECs and
C6 cells. To hopefully rectify this issue, additional experimentation with different blocking
buffers to include in the staining protocol was investigated
Experimentation with blocking buffers for the IF protocol involved the use of BSA,
NGS, and NDS experimental groups. Confocal imaging revealed that NDS was the most
appropriate buffer to use, and was successful at blocking for nonspecific binding of the
primary antibody on C6 cells. To further support this conclusion, a final stain using IF
protocol version 3 modified with NDS was performed on mono- and co-cultures of BAECs
and C6s. This study supported the use of NDS as a blocking buffer in the staining protocol,
and is sufficient to inhibit nonspecific binding.
Through these studies, a final protocol was developed for IF staining of tight
junctional proteins on mono- and co-cultures of endothelial and glial cells (Appendix 2.8).
This protocol can be used to verify the formation of tight junctional proteins in bench top
modeling of the BBB.
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Chapter 3 –Assessment of the Permeability across Monolayers of Endothelial and
Glial Cells

Section 3.0

Introduction

Following the establishment of a protocol to effectively stain for and image the
formation of tight junctions, the second aim of this thesis was to perform a functional
assessment of the in-vitro BBB cell cultures. These functional assessment experiments
evaluated the permeability of two distinct molecular weight FITC Dextrans. These static
studies incorporated BAECs and C6 cells cultured on 0.4 µm microporous transwell inserts
(Corning, Cat. No. 3401), allowing the partition of two separate chambers to simulate the
luminal and abluminal sides of the capillaries in the brain (Figure 24).

Figure 24| - Diagram of transwell insert showing the upper and lower compartment along
with the permeable membrane. C6 cells are cultured on the underside of the membrane while
the BAECs are cultured on the top of the membrane.93
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Transwell inserts are typically used to assess permeability of various known
compounds across a monolayer of cells25,39,73,90,94-100. This cell layer can be established in a
monoculture, co-culture, and tri-culture configuration25, such that the endothelial cells are
cultured on the top portion of the permeable membrane, astrocytes or pericytes cultured on the
underside of the membrane and/or on the bottom of the well. These studies will typically
involve the assessment of concentration of a known molecular weight molecule (such as
Dextran) as it passes through the membrane. Radiolabeled isotopes can also be employed to
determine permeability across the transwell membrane, but are less common. Regardless of
the compound used, it is possible to determine the change in concentration of the compound
in the media in the lower compartment in relation to the initial concentration in the media in
the upper compartment to determine a permeability coefficient for the established cell
monolayer. Therefore, the work in this chapter aimed to use the transwell insert model to
assess permeability across a dual layer of BAECs and C6 cells, to assess the formation of tight
junctions.
Section 3.1

Methods

Initial permeability assessments of the transwell inserts were performed to obtain a
baseline permeability coefficient. This coefficient describes the transport of both molecular
weight Dextrans across a microporous membrane not seeded with either cell type. This
information can then be compared to experimental data regarding inserts seeded with cells as
a method of accounting for the obstruction in diffusion due to the membrane itself.
Diffusion of each Dextran across the insert was assessed as concentration (in µl) as a
function of time. These changes in concentration over a given time period allow for the
calculation of the permeability coefficient (in cm/s) of the cultured monolayer in response to
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different sized compounds24. The variables shown in Eq. 3.0, include dQ/dt, which refers to
the amount of compound transported per minute (µg/min), A is the surface area of the
microporous membrane (cm2), Co is the initial concentration of the compound (µg/ml), and 60
is a conversion factor from minutes to seconds.

(3.0)

Section 3.1.1 Study 1 - Permeability Assessment of Transwell Inserts without Cells
This preliminary experiment involved the use of 12 inserts, arranged according to the
time points and Dextrans as shown in Figure 25. The transwell inserts (Figure 26) were first
precoated in the incubator overnight with a 1:1 mixture of BAEC and C6 cell culture media
(1.5 ml in basal chamber and 0.5 ml in the apical chamber). Following this incubation period,
the cell culture media was aspirated from each upper compartment and replaced with 500 µl
of Dextran.
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Figure 25| Location of time points in a 12-well plate for the permeability study of the 4 and
250 kDa Dextrans through transwell inserts not seeded with cells.

Figure 26| Transwell Permeable Supports used for functional permeability assessment of
cultured BBB. This insert is placed inside a well in a 6-well plate, effectively creating distinct
upper and lower compartments representing the luminal and abluminal surfaces of the
capillaries in the brain, respectively.
At each time point shown in Figure 25, a 500 µl sample was pipetted from the
abluminal compartment, placed in a quartz cuvette, and imaged using a Fluorometer (Jasco
FP-6500 Spectrofluorometer). A maximum intensity value (in arbitrary brightness units) was
then generated for each sample.
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Brightness data describing the working solutions and maximum basal chamber
fluorescence of the 4 and 250 kDa Dextran were also collected (See Figure 27). As each
Dextran has a distinct maximum fluorescence, it was necessary to calculate a brightness
coefficient (brightness per unit volume) for each Dextran (Eq. 3.1), where Bn is the
normalized brightness in arbitrary brightness units (au), Bm is the maximum brightness (au),
and V is the volume analyzed in the fluorometer (µl). The collected maximum intensity values
were then multiplied by this brightness coefficient to normalize the data.
(3.1)

Figure 27| Brightness values for 4 and 250 kDa FITC Dextran in the quartz cuvette
Spectrofluorometer. The undiluted Dextran shows the maximum fluorescence of the working
solution, while the diluted groups show the maximum fluorescence that can be expected
following each permeability study. (Maximum possible fluorescence in basal chamber is a 1:3
dilution of Dextran in media).
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Figure 28| Fluorescence values for the 4 and 250 kDa FITC Dextran. These numbers are not
normalized to the brightness per unit volume value assigned to each Dextran.
The raw brightness values are displayed in Figure 28, showing the difference in
maximum fluorescence between 4 and 250 kDa Dextran. The normalized data, which
provides a more accurate interpretation of the changes in abluminal Dextran concentration
over time, are shown in Figure 29. This data shows an increase in the concentration of both
compounds over a 25-minute time period. More importantly, this data reveals increased
diffusion of the smaller molecular weight Dextran through the porous membrane.
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Figure 29| Fluorescence values for the 4 and 250 kDa FITC Dextran. These numbers are
normalized to the brightness per unit volume value assigned to each Dextran.

Section 3.1.2 Study 2 - Permeability Assessment of Transwell Inserts with Cells
Once the control data describing the diffusion of both the 4 and 250 kDa Dextran
through the unseeded transwell inserts was collected, experimentation regarding hindered
diffusion through monolayers of BAECs and C6 cells was assessed. This set of
experimentation involved the use of control groups, including BAECs only and C6s only, to
show changes in permeability across the established monolayer when both cell types are
cultured separately. The orientation of the three experimental groups is shown in Figure 30.
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Figure 30| Cross-section of the permeable inserts showing the orientation of the three
experimental groups for the 4 kDa Dextran permeability assessment on seeded transwell
inserts.

Section 3.1.2.1

Permeability of 4 kDa FITC Dextran

This set of experimentation evaluated the diffusion of 4 kDa Dextran across the cell
culture layers. Three replicates of the experimental setup shown in Figure 31 were used in this
experiment. All 36 inserts were precoated in the incubator overnight with a 1:1 mixture of
BAEC and C6 cell culture media. To facilitate adhesion of the C6 cells to underside of the
membrane, 24 inserts were inverted and placed into individual wells in a 6-well plate. P13 C6
cells were cultured according to the protocol in Appendix 2.3, and passed onto the bottom of
the inserts (See Figure 32). Uncovered C6 cells were allowed to settle onto the inserts for 60
minutes in the laminar flow hood. The lid for the 6-well plate was then replaced and the cells
cultured in the incubator for an additional 60 minutes. Once sufficiently adhered to the bottom
of the membrane, the inserts were inverted again and placed back into their respective 12-well
plates, and allowed to culture for 24 hours.
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Figure 31| Experimental setup for the 4 kDa permeability study of seeded transwell inserts,
showing each control group and each time point.

Figure 32| Inverted orientation of transwell inserts in 6-well plate following passage of C6
cells onto the bottom of the membrane.
P5 BAECs were cultured according to the protocol in Appendix 2.3, and then passed
onto the upper compartment of 24 of the 36 inserts. All 3 sets of inserts were then allowed to
culture in the incubator for an additional 48 hours to ensure adequate monolayer confluency
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and sufficient interaction between the ECs and the glial cells in the Mix groups. Following
this culture period, the cell culture media in the luminal compartment of the inserts was
aspirated and replaced with 500 µl of 4 kDa Dextran. A 250 µl sample was taken from the
abluminal compartment of each well at the time points designated in Figure 31.
Due to the unavailability of the fluorometer used in the first permeability experiment,
each sample was pipetted into a foil-wrapped conical and stored in the refrigerator at the
designated time point. Fluorescence analysis for this set of experiments was performed on a
Microplate Spectrofluorometer (SPECTRAmax GEMINI XS Microplate Spectrofluorometer).
This machine required the use of an ELISA plate, and allowed simultaneous analysis of the
maximum brightness for each of the 36 samples. The use of a different fluorometer in this set
of experiments necessitated the reevaluation of the intensity values for the working solutions
of Dextran along with the maximum projected intensity of the diluted Dextran (1:3 dilution of
Dextran in cell culture media). The results of this analysis, shown in Figure 33, revealed a 5
and 3 fold increase in the intensity of the 4 and 250 kDa Dextrans, respectively. To make
legitimate comparisons between the first set of experimentation and this set, all calculated
brightness values shown in Figure 34 were divided by their respective fold increase in
maximum intensity. Additionally, it was necessary to account for the 3 week time period that
passed between collecting the samples from lower compartment and when these samples were
analyzed on the Spectrofluorometer. As per the manufacturer’s suggested storage
requirements, each sample was stored in a separate foil-wrapped conical inside the
refrigerator. Following these guidelines for extended storage, the supplier of the Dextran said
that there should be no issues with photobleaching of the fluorophores if the samples were
stored for less than 1 month.

61

Figure 33| Brightness values for 4 and 250 kDa FITC Dextran in the ELISA plate
Spectrofluorometer. The undiluted Dextran shows the maximum fluorescence of the working
solution, while the diluted groups show the maximum fluorescence that can be expected
following each permeability study. (Maximum possible fluorescence in basal chamber is a 1:3
dilution of Dextran in media).

Figure 34| Change in concentration of 4 kDa Dextran in the abluminal compartment for C6
only, BAEC only, and Mix groups. No statistical significance was supported between either
the time points or the experimental groups. (Note: these values have been normalized by their
fold increase over the maximum intensity value for the 4 kDa Dextran determined in the
initial permeability experiment). (Note: concentration values for the “No Cells” groups at the
15 and 20 minute time points exceeded the maximum y-axis value).
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Section 3.1.2.2

Permeability of 250 kDa FITC Dextran

The next set of experimentation was meant to evaluate the diffusion of the 250 kDa
Dextran across the cell culture layers. Three replicates of the experimental setup shown in
Figure 35 were used in this experiment. Methods for transwell insert preparation were the
same as in the 4 kDa study, replacing only the 4 kDa Dextran with the 250 kDa Dextran.

Figure 35| Same experimental setup as the 4 kDa study, except the 250 kDa Dextran was used
to assess monolayer permeability.
P10/12 BAECs were cultured according to the protocol in Appendix 2.3, and then
passed onto the luminal surface of 24 of the 36 inserts (as shown in Figure 35). All 3 sets of
inserts were then allowed to culture in the incubator for an additional 48 hours to ensure
proper adequate monolayer confluency and sufficient interaction between the ECs and the
glial cells in the Mix groups. Following this culture period, the cell culture media in the
luminal compartment of the inserts was aspirated and replaced with 500 µl of 250 kDa
Dextran. A 250 µl sample was taken from the abluminal compartment of each well at the time
points designated in Figure 35.
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Each sample taken was immediately pipetted into a well in the ELISA plate, and
analyzed for maximum brightness on the Microplate Spectrofluorometer. The results of the
experimentation with the 250 kDa Dextran are shown in Figure 36. Each of the values
presented have been normalized by their percent increase over the data collected using the
quartz cuvette fluorometer. It is also important to note that these samples did not sit in the
refrigerator before being analyzed on the Spectrofluorometer. However, after speaking with
the supplier of the Dextran, there should be no issues regarding the comparison of these
samples with those from the previous 4 kDa experiment, which did sit in the refrigerator.

Figure 36| Change in concentration of 250 kDa Dextran in the abluminal compartment for C6
only, BAEC only, and Mix groups. No statistical significance was supported between either
the time points or the experimental groups. (Note: these values have been normalized by their
fold increase over the maximum intensity value for the 250 kDa Dextran determined in the
initial permeability experiment).
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Section 3.1.2.3

Calculation of Permeability Coefficients for Transwell Insert

Studies
These experiments involving the 4 and 250 kDa Dextrans provided data regarding the
permeability of each compound across the membrane of the transwell inserts as a function of
time. This information, which was collected as arbitrary units of brightness, was normalized
by the brightness of each fluorophore per unit volume (au/µl). To determine the apparent
permeability coefficient using Eq. (3.0), the normalized transport rate of each dextran in au/µl
was converted to µg/min using Eq. (3.2), and then input into the Papp equation (simplified
values and units are shown in Eq. (3.3)).
3.2

3.3
The mean values for each time point in each experimental group were averaged as a
transport rate per minute and input into Eq. (3.2) to determine the changes in permeability.
The values shown in Table 3 indicate a decrease in the permeability coefficient due to the
presence of cells cultured on the inserts, and also reflect a significant difference between the
transport rates of each Dextran.
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Section 3.2

Discussion and Conclusions

This chapter analyzed the functional attributes of the BBB cell types in static culture,
through determination of the permeability of two distinct molecular weighted Dextrans. This
experimentation provided an alternative method for assessment of the extent to which tight
junctional proteins are being expressed. More importantly, this data can be used to infer the
extent to which these tight junctional proteins are able to interact and inhibit paracellular
transport of different sized compounds across the artificial BBB. However, it is also important
to realize that the decreases in permeability observed could also be due to the BAECs and C6s
physically clogging the pores, thereby inhibiting the amount of Dextran able to pass through
the membrane.
Initial experimentation with these transwell inserts was without cells, and aided in
determination of the permeability coefficient of the microporous membranes themselves.
Diffusion through non-seeded inserts of both the 4 and 250 kDa Dextran over a time period of
25 minutes was then calculated using maximum brightness values obtained using a
Spectrofluorometer. This information helped to provide a baseline diffusion coefficient across
the membrane prior to experimentation involving cells.
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Further experimentation involved the seeding of C6 cells only, BAECs only, and a
Mix group onto the inserts. The concentration data for 4 and 250 kDa Dextrans was collected
using a Microplate Spectrofluorometer (distinct from the previous fluorometer used), and as
such, the data was normalized by the percent increase in maximum brightness over the first
round of experimentation. These maximum brightness values for each experimental group at
each time point were then used to quantify the permeability coefficients of the transwell
inserts seeded with BAECs only, C6s only, or a co-culture of BAECs and C6s.
The data describing the 4 kDa Dextran is readily compared to values established in the
primary literature24, which have established a Papp of 93±5 E-6 cm/s for an insert not seeded
with cells, 2.7±0.2 E-6 cm/s for an insert seeded with endothelial cells, and 1.5±0.7 E-6 cm/s
for an insert seeded with both endothelial cells and astrocytes24. As evident in table 3, data
collected in the previous experiments is larger than the primary literature values by close to 30
cm/s in each experimental group, but remains in the same order of magnitude. Again, the
large standard error surrounding each of the values collected in this research (when compared
to the values established in the primary literature)24 suggest that a large enough sample size
was not evaluated to obtain consistently significant values of the permeability coefficient.
It is also important to discuss that the membranes from the transwell inserts used in the
previous experiments were not imaged or analyzed for cell monolayer confluency. This is
critical to mention because if there is not a confluent monolayer of ECs and/or astrocytes, it
would be much more simple for both the 4 and 250 kDa dextrans to pass from the top to the
bottom compartments of the insert. Confirmation of monolayer confluency can be achieved
through analysis of white light images of the transwell insert membrane. These images could
then be analyzed using imageJ to determine the percent of surface area covered by cells. This
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analysis would provide evidence of monolayer confluency, and further support the data
suggesting an inhibition in permeability due to the presence of the ECs and astrocytes.
While this data does not support a significant difference between experimental groups,
it does lay the groundwork for further experimentation involving regulated diffusion across a
layer of cells. Specifically, this work aided in the development of a permeability testing
protocol (provided in Appendix 2.9) that can be applied to future experimentation involving
dynamic BBB models.
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Chapter 4 – Discussion and Conclusion

Section 4.0

Overview

The experimentation involving IF protocol development along with the permeability
assessments have created a solid foundation for BBB research in the Tissue Engineering Lab
at Cal Poly. The final staining protocol that was developed provides the ability to visually
assess the development of the BBB in-vitro through fluorescently labeling tight junctional
proteins. This allows for assessment of BBB characteristics not only in static culture
conditions, but also in a dynamic environment such as a perfusion bioreactor system.
Additionally, the permeability studies provided the first functional assessment of the BBB
models established in this lab. These experiments provided the initial look at diffusion across
a monolayer of endothelial cells, astrocytes, and co-culture of ECs and astrocytes. This data
can be used to speculate on barrier formation in a tubular scaffold, and the way with which
these cells will behave in a more dynamic environment, assuming that the static
characteristics translate well to a dynamic system. Overall, these experiments have provided
groundwork for the development of a dynamic model of the BBB in a custom perfusion
bioreactor system.
Section 4.1

IF Protocol Development

The first requirements of assessing the establishment of the BBB in-vitro was the
development of an Immunofluorescence protocol that allowed for discrete staining of tight
junctional proteins. Through labeling of these BBB specific proteins, it is possible to assess
not only the formation of the BBB in culture, but also changes in the extent to which this
barrier is formed determined by the volume of cells expressing these tight junctional proteins.

69

It was important to investigate the expression of the ZO-1 and Claudin-5 proteins because this
information can be directly correlated with previously established values found in
literature18,25,65,101,102. Because establishment of tight junctional proteins and the ability to
label these proteins is so vital to the establishment of an in-vitro model of the BBB, the
development of an adequate IF protocol to stain for these tight junctional proteins was the first
priority of this research.
IF Protocol version 1 (Appendix 2.0) had proven to be unsuccessful at staining for
tight junctional proteins. Therefore, elements from a separate IF protocol (Appendix 2.1) that
had been developed for labeling PECAM-1 proteins on hUVECs were incorporated into a
hybrid IF protocol (IF Protocol version 2) for BBB research (Appendix 2.2). The success of
the stain for ZO-1 on BAECs and hUVECs indicated that it was appropriate to continue
experimentation involving tight junctional protein labeling in static culture conditions.
While IF protocol version 2 was sufficient to show the presence of tight junctional
proteins in static culture, it was not clear whether this protocol would be able to show
upregulation of protein expression as the endothelial cells formed a more confluent
monolayer. The next set of experimentation investigated whether tight junctional protein
expression would be upregulated as adjacent endothelial cells came into closer contact in
higher confluency culture environments.
Qualitative analysis of the images obtained from IF staining of BAECs showed an
upregulation in the expression of ZO-1 in a monoculture of BAECs as the monolayer became
more confluent. This supports the idea that tight junctional proteins will be expressed in larger
amounts on endothelial cells that are in close contact with each other.
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The confluency experiments confirmed the use of the IF protocol to determine
upregulation of tight junctional protein expression in response to increases in monolayer
confluency. It was then necessary to determine other environmental cues that aid in
upregulation of tight junctional protein expression. One of the most critical factors to
establishment of the BBB is the interaction between the different cell types. Specifically, the
interaction between the endothelium and the glial cells plays a crucial role in barrier
formation. These experiments investigated the change in tight junctional protein expression as
a function of BAEC and C6 co-culture. Additionally, these experiments were divided into
three different groups depending upon the orientation of each cell type. The experimental
groups were monocultures of BAECs and C6s, BAECs grown on top of C6s, C6s grown on
top of BAECs, and a homogeneous mixture of the two cell types.
The first co-culture experiment investigated the changes in ZO-1 expression when
BAECs are cultured on top of a layer of C6 cells. The experimental groups included BAECs
only, C6s only, and three groups of BAECs on top of C6s. The fluorescence imaging revealed
positive ZO-1 expression in BAEC monoculture, and residual staining in the C6 only group.
The observed fluorescence in the C6 only group could mean that the IF protocol was allowing
for nonspecific binding of the primary antibody, or it could mean that the ZO-1 protein was
being expressed on the C6 cells. Therefore, It was necessary to determine if other tight
junctional proteins were being labeled on the astrocytes, to either confirm or rule out the issue
of nonspecific binding. Additionally, en-face analysis of the co-culture images revealed a
slight increase in the brightness of the fluorophores, suggesting an increase in ZO-1
expression. It is important to note that the images of the co-culture group show a moss-like
coating of the ZO-1 protein on the layer of cells, possibly indicating a change in cell
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morphometry or a limitation in the resolution of the fluorescence microscope. Due to the lack
of similar references in literature, it was assumed that these issues relating to the imaging
were a function of the limitations of the microscope.
In the following experiment, an IF stain was performed using IF protocol 2 to get a
better understanding of the changes in tight junctional protein expression a function of
endothelial cell and glial cell co-culture. The critical piece of information gained from this
study was the fluorescence observed on monocultures of C6 cells. In every case, C6 cells
showed positive IF staining for ZO-1, PECAM-1, and Claudin-5. As each of these proteins in
specific to endothelial cells, it was necessary to investigate the reason behind this
fluorescence. After some examination, it was decided that fluorescence in C6 monocultures
following IF staining of tight junctional proteins was due to nonspecific binding of the
primary antibody. This was due to issues associated with the blocking buffer that was part of
the current IF protocol. It is also important to note that the occurrence of nonspecific binding
of the primary antibody suggests that the previous results are not necessarily indicative of the
formation or upregulation of tight junctional proteins. Specifically, the results suggesting an
increase in tight junctional protein expression due to both monolayer confluency and coculture with astrocytes could in fact be due to nonspecific binding. Because the blocking
buffer used in IF protocol version 2 was allowing for this nonspecific binding, investigations
into a different blocking buffer were necessary
To correct for this nonspecific binding of the primary antibody, three different
blocking buffers were used in the IF protocol and compared for fluorescence. Bovine serum
albumin, normal goat serum, and normal donkey serum were used as blocking buffers during
an IF stain for Claudin-5 on C6 cells. This stain was performed on C6 cells to investigate the
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ability of the blocking buffer to block for nonexistent proteins on C6 cells. Additionally,
Claudin-5 was stained in this study, as ZO-1 expression has been observed on non-epithelial
cell types92, and may not be the strongest indicator of endothelial cells.
Once each of the experimental groups was stained using a different blocking buffer,
the groups were imaged on the multiphoton laser scanning microscope. These images showed
that BSA was unable to block for nonspecific binding of the primary antibody, while NGS
and NDS revealed no fluorescence. Further examination of these two blocking buffers led to
the replacement of BSA with NDS in the IF protocol. This choice was mainly due to the
compatibility of the donkey serum with the donkey anti-rabbit secondary antibody used.
Following the replacement of BSA with NDS in the staining protocol, it was then
necessary to perform a co-culture experiment with ECs and glial cells to determine the
efficacy of the finalized IF protocol in staining for tight junctional proteins. This study
included BAEC and C6 monocultures along with a Mix group. Confocal image analysis
revealed positive Claudin-5 expression in the BAEC only and Mix groups. The C6 only group
showed no fluorescence in either the positive or negative control groups, indicating that the
NDS was sufficient to block for nonspecific binding on both glial cells and ECs.
This final proof of concept stain supports the use of this IF staining protocol for
purposes of labeling tight junctional proteins in static mono- and co-cultures. This protocol
can subsequently be used to determine the presence of tight junctions not only in these static
culture conditions, but also in dynamic models of the BBB. This IF protocol can be used to
identify the extent of tight junction formation in in-vitro models of the BBB through
histological sectioning and staining of the seeded scaffolds.
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Section 4.2

Permeability Studies

Following the development of a protocol to image the formation of tight junction
proteins, it was necessary to investigate the functional attributes of these junctions.
Specifically, permeability of two different molecular weighted Dextrans across monolayers of
BAECs and C6 cells was investigated. This data provided information on the changes in
membrane permeability due to the presence of BAECs alone, C6s alone, and a co-culture of
both BAECs and C6s. To culture these cells, permeable transwell inserts were used to assess
transport of 4 kDa and 250 kDa Dextrans.
To gain an accurate understanding of the transport across a monolayer of cells, it was
first necessary to understand the transport of a known compound across the membrane on
which the cells are grown. This experimentation involved the addition of the 4 and 250 kDa
Dextrans to the luminal port of 12 non-seeded transwell inserts. Diffusion of the Dextran was
assessed at 5-minute intervals to determine a transport rate per minute. Graphs of the data
show a gradual increase in the concentration of Dextran over 25 minutes. More importantly,
the data shows a significant difference in permeability between the two different Dextrans,
supporting the hypothesis that a larger sized molecular weighted compound will not as readily
cross the membrane.
Once the transport rates of both Dextrans across an unseeded permeable insert were
established, it was necessary to introduce cells to the system to influence the formation of the
BBB. For the experiment involving the 4 kDa Dextran, the data was analyzed using a one-way
ANOVA test, due to the comparison of multiple variables across multiple time points. This
analysis revealed no statistically significant differences between the 5, 10, 15, and 20-minute
time periods for each of the experimental groups. Additionally, there were no significant
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differences between each of the groups (C6 only, BAEC only, and Mix) at each time point.
Therefore, no inferences can made as to which experimental group resulted in the least
diffusion across the transwell insert. However, at each time point, the data shows a trend
suggesting that the C6 only group allowed the most Dextran to pass through the insert, while
the Mix group allowed the least amount of Dextran through, possibly due to high number of
cells that were able to clog the pores of the insert. This trend is true for all time points.
Additionally, there is a trend showing an increase in the amount of Dextran present on the
abluminal chamber of the transwell insert as time increases from 5 to 20 minutes. This lack of
statistical significance (and large standard error bars) coupled with data that trends in the
expected manner suggests that the sample size for this experiment was not large enough to
provide an adequate representation of the experimental situation.
The same protocol was applied to the 250 kDa Dextran. Data collected from this
experiment was also analyzed using a one-way ANOVA test, and yielded similar results.
There was no statistically significant difference between any of the 5, 10, 15, and 20-minute
time points. Additionally, There was no significant difference between the C6 only, BAEC
only, and Mix experimental groups at each time point. Similar to the 4 kDa experiment, the
data does show a positive correlation between the concentration of Dextran in the abluminal
chamber of the insert and time. The data also shows a trend suggesting that the C6 only group
allows the greatest amount of Dextran to pass through the membrane, while the Mix group
allowed the least amount to diffuse through. Again, this lack of statistical significance
between the time points and between the experimental groups combined with the fact that the
data from the 4 kDa experiment showed similar trends, suggests that the lack of statistical
significance is due to a deficit in the necessary sample size.
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This data was, however, able to provide useful and relevant information regarding the
permeability coefficients (Table 3) of the transwell insert both without cells, and in the
presence of the three treatment groups. The coefficients shown in Table 3 from Chapter 3,
which take into account the initial concentration of the Dextran in the luminal chamber, the
surface area of the permeable membrane, and the final concentration of the Dextran in the
abluminal chamber, describe the rate at which a given compound is able to diffuse across a
permeable membrane. These values collected in the 4 kDa and 250 kDa experiments are
comparable to those found in literature 24.
Section 4.3

Future Work

While this research presents a step forward in our lab’s understanding of modeling the
BBB, there is a significant amount of future work that would enhance the data collected here
and solidify further research into an in-vitro model of the BBB. The first step would be the
enhancement of the imaging performed to detect the formation of tight junctions. As
discussed in Chapter 1, ZO-1 and Claudin-5 are only two of the proteins that form the barrier
to paracellular diffusion. Therefore, the staining and imaging performed in Chapter 2 would
be greatly strengthened through the addition of other primary antibodies tailored to label other
BBB membrane-bound proteins. Additionally, it has been suggested that the ZO-1 protein can
be found on astrocytes and other non-epithelial cell types92,101. Therefore, while the use of the
ZO-1 antibody does suggest the formation of tight junctions in mono- and co-cultures of
endothelial cells, overall tight junction formation would better be assessed through the use of
one or more additional primary antibodies, such as ZO-2, ZO-3, Claudin-3, Claudin-12, and
the Occludin family39,90,103.
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The next future step would include the use of a TEER system to measure the electrical
resistance of each experimental group in the permeability studies from Chapter 3. TEER
measurement involves the use of small electrodes to induce a current across a cultured
membrane. The resistance experienced by this current as a result of EC-EC junctions is then
measured, to provide evidence of the “tightness” of each cell junction and overall monolayer
confluency. The majority of in-vitro BBB models found in the primary literature will evaluate
the TEER value for tissue-engineered construct23-25,39,73,90,91,94,96,99,103,104. Therefore, TEER in
these models is well characterized, resulting in a wealth of peer-reviewed data, which
provides a wealth of information with which to compare experimental values. This type of
analysis was not included in this research due to cost restraints, but would provide a much
more in-depth investigation into the ability of our lab on campus to establish a functional
model of the BBB.
The use of a TEER measurement system, such as the EVOM2 Epithelial
Voltohmmeter, in a static BBB model (such as those found in transwell insert studies) is well
characterized, and involves the placement of two electrodes on a cultured monolayer of
endothelial cells. A current is then run across the monolayer, and the resistance is calculated.
However, the incorporation of a TEER measurement system into a dynamic model of the
BBB is much more difficult. To provide reliable data, it would be necessary to determine both
axial and transluminal TEER values through a tubular construct. This would most likely
involve the use of permanent electrodes incorporated into the bioreactor itself for continuous,
real-time TEER monitoring.
Another piece of future work, which directly applies to the data gathered in this
research, would be the re-evaluation of the permeability coefficients of the transwell inserts to
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the 4 kDa and 250 kDa Dextrans with a much larger sample size. This experimentation will
hopefully provide a general affirmation of the data collected in the studies from Chapter 3,
and reduce the variability indicative of experiments using too few replicates.
Additionally, it is necessary to determine the inhibition in permeability is due to
formation of tight junctions, or if it is due to the cells physically clogging the pores of the
transwell insert membrane. This can be accomplished one of two ways: either through RNA
sequencing to determine the relative amount of tight junctional proteins that are being
expressed, or through the use a control group using non-tight junction forming cells. The
RNA sequencing method would follow the same protocol as established in the 4 and 250 kDa
Dextran studies, but would then involve the removal of the cells from the transwell membrane
to determine RNA expression of ZO-1, Claudin-5, and PECAM-1. This would help to
determine if these proteins are being upregulated in the co-culture conditions established on
the transwell insert membrane. A more simplistic approach would be the use of a separate cell
type, such as 3T3 Fibroblasts, in the same experimental procedure. These fibroblasts would be
seeded onto the transwell membrane in the same method as the ECs and C6s were, but would
not be expected to form tight junctions. This would allow the comparison between tight
junction forming groups and non-tight junction forming groups to determine if the changes in
permeability across the insert were due to BBB formation or just clogging of the pores by the
cells themselves.
The final piece of future work would include the addition of a shear element to the cocultures of ECs and astrocytes. This would most likely come in the form of a tissueengineered blood vessel. The BAECs and C6 cells used in this research would be pressure
sodded onto a microporous cylindrical scaffold housed inside of a perfusion bioreactor
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system. Specifically, the type of perfusion bioreactor system developed by Amin
Mirzaaghaeian105 in addition to the porous PLGA scaffolds developed by Deven Patel106
would enable the culture of such a dynamic in-vitro BBB model. Translation from static
culture conditions into a dynamic model such as the one developed in Cal Poly’s Tissue
Engineering lab would provide not only a robust model of the BBB, but one that enables
sectioning, imaging, and functional analysis of the cultured tissue. This is in direct contrast to
the use of multiple capillary tubes for scaffolds, as a seen in the CellMax system, which does
not facilitate straightforward analysis due to restraints around the scaffold material and overall
bioreactor design. The use of the bioreactor system developed at Cal Poly would allow for the
formation of a confluent endothelium inside the tubular construct, while also allowing for the
interaction of the endothelial cells with astrocytes and the introduction of a shear stress
element to the ECs. Additionally, it would be prudent to incorporate a custom TEER
measurement system into the dynamic model, to allow for real time monitoring of monolayer
confluency and intercellular adhesion. This next step would be one of the final pieces of
experimentation to support the formation of a functional model of the BBB in our lab.

Section 4.4

Conclusion

The research presented here describes an assessment of the extent to which tight
junctions can be formed in static mono- and co-culture situations with ECs and astrocytes, in
addition to an assessment of the permeability of cells in culture. Chapter 2 presented the steps
used to establish a practical protocol for immunohistochemical staining of cell surface
proteins indicative of tight junction formation. This protocol was used to evaluate the
expression of ZO-1 and Claudin-5 in mono- and co-cultures of BAECs and C6 cells to
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establish a metric for determination of BBB formation in static culture. The next set of
experiments in Chapter 3 introduced a more functional assessment of these proteins. These
studies investigated the ability of these cells (both separately and in co-culture) to decrease the
permeability of known compounds across the transwell insert membrane. In this case, the
compounds used were fluorescently labeled 4 kDa and 250 kDa Dextrans. The diffusion of
these compounds through the transwell inserts was used to evaluate the permeability
coefficient of the cultured BBB.
This research presents a step forward for the Tissue Engineering lab at Cal Poly in
terms of its ability to accurately and efficiently model the phenotypic and functional
attributes of the BBB. While the efforts put forth in this research provide pertinent
information regarding modeling of this barrier, there is still much experimentation to be
performed to fully understand and adequately mimic the functional characteristics of the BBB.
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Appendix 2.0

IF Protocol Version 1

1.
2.
3.
4.
5.
6.

Fix cells in 4% Paraformaldehyde (PFA) for 30 mins at 4°C.
5 mins. PBS
15 mins. 0.3% Triton X-100 diluted in PBS
Rinse slide with PBS, then do a 2x5 min. wash with PBS
60 min. in blocking buffer at room temp.
Dilute primary antibody (usually 1:50) in working buffer and add 200µl to each slide.
Cover with foil and leave at 4°C overnight.
7. Rinse with PBS, then do 3x10 min. PBS washes
8. Rinse with working buffer
9. Add secondary antibody diluted (usually 1:400) in working buffer for 60 mins. at room
temp.
10. Rinse with PBS, then do 3x10 min. PBS washes
11. 1 min. DAPI
12. 5 mins. PBS
13. 5 mins. dH2O.
14. Mount with mounting medium and coverslip
Blocking buffer recipe:
50mM Glycine, 2% donkey serum, 2% BSA
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Appendix 2.1

IF Protocol for PECAM-1 stain on hUVECs

1. Remove cell culture media and fix cells in 10% Formalin for 15 minutes.
2. 3x PBS washes for 5 minutes each.
3. Permeabilize cells in 0.2% Triton X-100
4. 3x PBS washes for 5 minutes each.
5. Block for non-specific binding using 6% Bovine Serum Albumin (BSA)
6. Incubate in Primary Antibody and 6% BSA for 50 minutes.
7. 3x PBS washes for 5 minutes each.
8. ** Steps 8-12 are LIGHT SENSITIVE**
9. Incubate in secondary antibody and 6% BSA for 50 minutes.
10. 3x PBS washes for 5 minutes each.
11. Counter stain using Bisbenzimide for 15 minutes.
12. 1x PBS wash for 5 minutes.
13. Remove coverslips from each well, mount to glass slides using mounting medium, and
allow to dry for 24 hours.
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Appendix 2.2

IF Protocol Version 2

1. Remove cell culture media and fix cells in 10% Formalin for 15 minutes.
2. 3x PBS washes for 5 minutes each.
3. Permeabilize cells in 0.2% Triton X-100
4. 3x PBS washes for 5 minutes each.
5. Block for non-specific binding using 6% Bovine Serum Albumin (BSA)
6. Incubate in Primary Antibody and 6% BSA for 24 hours.
7. 3x PBS washes for 5 minutes each.
a. ** Steps 8-12 are LIGHT SENSITIVE**
8. Incubate in secondary antibody and 6% BSA for 50 minutes.
9. 3x PBS washes for 5 minutes each.
10. Counter stain using Bisbenzimide for 15 minutes.
11. 1x PBS wash for 5 minutes.
12. Remove coverslips from each well, mount to glass slides using mounting medium, and
allow to dry for 24 hours.
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Appendix 2.3

Cell Culture and Passage Protocol
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Appendix 2.4
DAKO Autostainer IF stain for ZO-1, Claudin-5, and PECAM-1
using IF Protocol Version 2

Section 2.0

Autostainer Experimentation

Due to the volume of IF staining necessary to obtain the right sample size, the use of
an automated staining machine (Dako, Cat. No. S380031) was considered. This machine
allows for a maximum of 48 slides to be stained according to a predetermined protocol, which
is programmed in by the user. The protocol that was programmed into the autostainer software
was the IF protocol from (Appendix 2.4). This system should allow the simultaneous staining
for PECAM-1, Claudin-5, and ZO-1 across all experimental groups (BAECs alone, C6s alone,
BAECs grown on top of C6s, C6s grown on top of BAECs, and a Mix group).
Section 2.3.1 PECAM-1 Test Run
Before running the large-scale experiment in the autostainer, it was necessary to
ensure that the protocol had been programmed in correctly, and that the system would
accurately stain each slide to ensure successful fluorescence imaging. Therefore, an IF stain
for PECAM-1 was performed on HUVECs, due to the robust procedure previously established
for this stain.
The positive control group showed ZO-1 expression, while the negative control did
not. This indicated that the autostainer successfully executed the programmed IF protocol and
produced usable images on the widefield fluorescence microscope.
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Figure 37| IF stain images from test run on Autostainer. (A) Primary+Secondary antibody
stain positive for ZO-1 expression. (B) Negative control group showing lack of ZO-1
expression. (C) BBI imaging showing location of cells.

Section 2.3.2 Co-Culture Experimentation
Due to the success of the test run on the autostainer, the IF protocol (for what?)
(Appendix 2.2) was programmed into the software. For this co-culture experiment, both cell
types were arranged into monoculture groups and also into the orientations shown in Figure
38. Cell counts used for each of the treatment groups are listed in Table 2. To construct a
more complete picture of the formation of BBB tight junctional proteins, an additional stain
was added for Claudin-5. The treatment groups, including the positive and negative controls,
for each of the ZO-1, PECAM-1, and Claudin-5 primary antibodies are shown in Figure 39.
For the groups with C6 cells on the bottom of the BAECs, the C6s were cultured for 24 hours
before adding BAECs. The same was performed for the groups with BAECs on the bottom,
allowing the ECs to culture for 24 hours before adding the C6s.
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Figure 38| Orientation of cells used in co-culture experimentation (BAECs grown on top of
C6 cells, C6s grown on top of BAECs, and Mix groups). The eye indicates direction through
which these cells were imaged using the Multiphoton Laser Scanning Microscope.

C6
BAEC

C6
BAEC

BAECs on top of C6s
Count 1
1.07E+06
Count 2
1.01E+06
Count 1
5.25E+05
Count 2
6.67E+05
Mix
Count 1

5.27E+06

Count 2
Count 1
Count 2

5.04E+06
7.77E+05
5.64E+05

C6
BAEC

C6
BAEC

C6s on top of BAECs
Count 1
6.05E+06
Count 2
5.31E+06
Count 1
3.86E+05
Count 2
3.38E+05
Alone
Count 1

5.17E+06

Count 2
Count 1
Count 2

5.54E+06
3.86E+05
3.38E+05

Table 2| Cell counts indicating the concentration of cells added to each well of each
experimental group. (Units are in cells/ml)
After a final co-culture period of 24 hours, the coverslip on which each experimental
group was cultured was mounted to a glass slide (face up) using mounting adhesive. To
prevent the cells from desiccating, PBS was pipetted onto each of the slides after they were
mounted inside of the autostainer. Once the system had finished performing the IF stain, the
majority of the coverslips were blown off of the slides. This made imaging very difficult, and
only images for Claudin-5 staining of the BAEC on top of C6s and the Mix groups was
possible (Figure 40).
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Figure 39| Location of each experimental group for IF stain for ZO-1, PECAM-1, and
Claudin-5. This experiment investigated the expression of these three cell surface proteins
when BAECs and C6s are co-cultured (BAECs grown on top of C6 cells, C6s grown on top of
BAECs, and a mixture of the two cell types).
The usable slides were imaged (Figure 40) revealing typical staining for the antibody
and cell nuclei (both BAECs and C6s). Although no useful data regarding brightness of
protein expression was obtained in this experiment, this test did show positive expression of
Claudin-5 in co-culture groups for the first time. However, due to
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Figure 40| IF images from initial co-culture experimentation using the autostainer. (A, E)
Primary+Secondary antibody groups showing positive ZO-1 expression. (B, F) BBI stain for
cell nuclei. (C, G) CT Red stain for BAECs and (D, H) CT Violet stain for C6s.
the issues associated with the current protocol for using the autostainer, the following coculture experimentations were conducted manually.
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Appendix 2.5
Hanne107

Autostainer Protocol Taken from Senior Project by Nicholas
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Appendix 2.6
Protocol for IF Stain for ZO-1, Claudin-5, and PECAM-1 on C6
only, BAEC only, C6/BAEC, BAEC/C6, and Mix Experimental Groups
1. Trypsinize BAECs and C6s and plate onto separate coverslips and allow to culture for
24 hours.
2. Trypsinize BAECs to plate on top of C6s, C6s to plate on top of BAECs, and a group
of BAECs and C6s to mix together, and allow to culture for 24 hours.
3. Remove cell culture media and fix cells in 10% Formalin for 15 minutes.
4. 3x PBS washes for 5 minutes each.
5. Permeabilize cells in 0.2% Triton X-100
6. 3x PBS washes for 5 minutes each.
7. Block for non-specific binding using 6% Bovine Serum Albumin (BSA)
8. Incubate in Primary Antibody and 6% BSA for 24 hours.
9. 3x PBS washes for 5 minutes each.
a. ** Steps 8-12 are LIGHT SENSITIVE**
10. Incubate in secondary antibody and 6% BSA for 50 minutes.
11. 3x PBS washes for 5 minutes each.
12. Counter stain using Bisbenzimide for 15 minutes.
13. 1x PBS wash for 5 minutes.
14. Remove coverslips from each well, mount to glass slides using mounting medium, and
allow to dry for 24 hours.
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Appendix 2.7
Results from IF Stain for ZO-1, Claudin-5, and PECAM-1 on C6
only, BAEC only, C6/BAEC, BAEC/C6, and Mix Experimental Groups
The BAEC only groups were positive for PECAM-1, Claudin-5, and ZO-1 expression as
indicated by the primary+secondary groups (Figure 41). CT Red images showed no
significant staining, which is expected as only C6 cells were stained with CT Red. Composite
imaging of the antibody stains and BBI indicate localization of protein expression to the cell
membrane. The negative control groups shown in Figure 42 did not show protein labeling,
indicating a lack of nonspecific binding.
The C6 only groups were also positive for PECAM-1, Claudin-5, and ZO-1 expression
as indicated by the primary+secondary groups (Figure 43). Cell Tracker images were positive
for C6 cells, which is expected, as this is a monoculture of C6 cells. Composite images reveal
localization of protein expression to the cell membrane. The expression of these EC-specific
proteins suggests nonspecific binding of either the primary or the secondary antibody. We can
assume that the primary antibody is nonspecifically binding, as the negative control groups
shown in Figure 44 indicate a lack of nonspecific binding on the part of the secondary
antibody.
The BAECs grown on top of C6s group also showed expression of PECAM-1, but
showed a trend toward increased fluorescence of the ZO-1 and Claudin-5 antibodies (Figure
45). Because these slides were imaged from underneath (Figure 19), the CT images indicate
the presence of C6 cells. Again, composite imaging of the protein expression and nuclear
staining indicates localization of protein expression to the cell membrane. The negative
control groups shown in Figure 46 indicate a lack of nonspecific binding.
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The C6/BAEC group also indicated PECAM-1 expression and an upregulation in the
expression of Claudin-5 and ZO-1 (Figure 47). This group showed less CT fluorescence, as
would be expected since these slides were imaged from the bottom. The composite images of
primary+secondary and BBI groups show protein expression localized to the membrane.
Again, the negative control groups shown in Figure 48 indicate a lack of nonspecific binding.
The final group consisting of BAECs and C6s mixed together were also positive for
PECAM-1, and showed an upregulation in expression of Claudin-5 and ZO-1 (Figure 49). As
the C6s were mixed in with the BAECs, the CT images revealed the presence of C6 cells. Cell
surface proteins are localized to the membranes, as confirmed by the composite images. The
negative control groups shown in Figure 50 indicate a lack of nonspecific binding.
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Figure 41| IF staining for BAEC only positive control groups. (A-D) indicate PECAM-1
primary antibody group, (E-H) indicate Claudin-5 primary antibody group, and (I-L) indicate
ZO-1 primary antibody group. Positive control groups (A, E, I) indicate positive protein
expression (B, F, J) show cell location, and composite images are shown in D, H, L. Location
of C6 cell nuclei seen in CT images (C, G, K).
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Figure 42| IF stain images for BAEC only groups. Negative control groups (A, D, G) indicate
a lack of nonspecific binding of the antibody. BBI images (B, E, H) reveal nuclei of both cell
types, while CT images (C, F, I) show location of C6 cells.
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Figure 43| IF staining for C6 only experimental groups. (A-D) indicate PECAM-1 primary
antibody group, (E-H) indicate Claudin-5 primary antibody group, and (I-L) indicate ZO-1
primary antibody group. Positive control groups (A, E, I) indicate positive protein expression
(B, F, J) show cell location, and composite images are shown in D, H, L. Location of C6 cell
nuclei seen in CT images (C, G, K).
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Figure 44| IF stain images for C6 only groups. Negative control groups (A, D, G) indicate a
lack of nonspecific binding of the antibody. BBI images (B, E, H) reveal nuclei of both cell
types, while CT images (C, F, I) show location of C6 cells.
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Figure 45| IF staining for BAEC on top of C6 experimental groups. (A-D) indicate PECAM-1
primary antibody group, (E-H) indicate Claudin-5 primary antibody group, and (I-L) indicate
ZO-1 primary antibody group. Positive control groups (A, E, I) indicate positive protein
expression (B, F, J) show cell location, and composite images are shown in D, H, L. Location
of C6 cell nuclei seen in CT images (C, G, K).
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Figure 46| IF stain images for BAEC on top of C6s groups. Negative control groups (A, D,
G) indicate a lack of nonspecific binding of the antibody. BBI images (B, E, H) reveal nuclei
of both cell types, while CT images (C, F, I) show location of C6 cells.
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Figure 47| IF staining for C6s on top of BAECs experimental groups. (A-D) indicate
PECAM-1 primary antibody group, (E-H) indicate Claudin-5 primary antibody group, and (IL) indicate ZO-1 primary antibody group. Positive control groups (A, E, I) indicate positive
protein expression (B, F, J) show cell location, and composite images are shown in D, H, L.
Location of C6 cell nuclei seen in CT images (C, G, K).
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Figure 48| IF stain images for C6s on top of BAECs groups. Negative control groups (A, D,
G) indicate a lack of nonspecific binding of the antibody. BBI images (B, E, H) reveal nuclei
of both cell types, while CT images (C, F, I) show location of C6 cells.
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Figure 49| IF staining for Mix experimental groups. (A-D) indicate PECAM-1 primary
antibody group, (E-H) indicate Claudin-5 primary antibody group, and (I-L) indicate ZO-1
primary antibody group. Positive control groups (A, E, I) indicate positive protein expression
(B, F, J) show cell location, and composite images are shown in D, H, L. Location of C6 cell
nuclei seen in CT images (C, G, K).
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Figure 50| IF stain images for Mix groups. Negative control groups (A, D, G) indicate a lack
of nonspecific binding of the antibody. BBI images (B, E, H) reveal nuclei of both cell types,
while CT images (C, F, I) show location of C6 cells.
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Appendix 2.8

IF Protocol Version 3

1. Remove cell culture media and fix cells in 10% Formalin for 15 minutes.
2. 3x PBS washes for 5 minutes each.
3. Permeabilize cells in 0.2% Triton X-100
4. 3x PBS washes for 5 minutes each.
5. Block for non-specific binding using 3% Normal Donkey Serum (NDS)
6. Incubate in Primary Antibody and 3% NDS for 24 hours.
7. 3x PBS washes for 5 minutes each.
** Steps 8-12 are LIGHT SENSITIVE**
8. Incubate in secondary antibody and 3% NDS for 50 minutes.
9. 3x PBS washes for 5 minutes each.
10. Counter stain using Bisbenzimide for 15 minutes.
11. 1x PBS wash for 5 minutes.
12. Remove coverslips from each well, mount to glass slides using mounting medium, and
allow to dry for 24 hours.
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Appendix 2.9

Permeability Testing Protocol

1. Open pack of 12 sterile transwell inserts inside the laminar flow hood.
2. Add 1.5 ml of media to the lower compartment and 0.5 ml of media to the upper
compartment. Allow to precoat for 24 hours.
3. Transfer and invert each transwell insert to a well in 2 6-well plates. Note: do not
discard 12-well plates with media.
4. Trypsinize C6 cells, and spin down to a concentrated solution.
5. Add 2-3 drops of C6 solution to the inverted transwell insert membrane.
6. Leave cover off of 6-well plates and allow cells to adhere for 90 minutes.
7. Place cover on 6-well plates and place in incubator for 2 hours.
8. Invert inserts again so they are in the correct orientation, place back into 12-well plate,
and add trypsinized BAECs to upper compartment.
9. Following a 48-hour culture period, aspirate media from the upper compartment, and
replace with 500µl of FITC Dextran at a concentration of 100µg/ml.
10. Sample media from lower compartment at 5-minute intervals, placing each sample in
one well of an ELISA plate.
11. Once all samples are collected, place ELISA plate into Spectrofluorometer to obtain
brightness values for each well.
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